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ABSTRACT
Using Phased Whole Genome Sequence Data to Better Understand the Role of
Compound-Heterozygous Variants in Pediatric Diseases
Dustin B. Miller
Department of Biology, BYU
Doctor of Philosophy
A compound-heterozygous variant occurs when a child inherits a variant from each
parent, with these variants occurring at a different position within the same gene and on opposite
homologous chromosomes. These inherited variants may result in two nonfunctional versions of
the same gene. Compound-heterozygous variants cannot be identified unless a patients’ DNA
sequence data is phased. Phasing is a computationally demanding process that requires the use of
multiple software tools in order to determine which nucleotide was inherited from which parent.
First, in Chapter 1, we review the literature to better understand what research has been
conducted on the role of compound-heterozygous variants in pediatric cancers and what methods
are being used to identify them. In Chapter 2, we develop a pipeline to make it easier for us and
other researchers to phase and identify compound-heterozygous variants using VCF files from
trios or individuals. We then use this pipeline in Chapter 3 to survey the prevalence of
compound-heterozygous variants across 7 pediatric disease types. We show the importance of
identifying compound heterozygous and what information would be missed if this variant type
was not included in study design. In Chapter 4, we develop a software tool to phase trio data
using a combination of Mendelian inheritance logic and an existing phasing software program.
We show that our software tool increases the total number of variants that can be phased.
Finally, in Chapter 5, we use phased data of three nuclear families, each family having one child
with pediatric cancer, to evaluate the potential to use inherited genomic variants to inform
diagnostic decisions. The work contained within this dissertation shows the importance of not
overlooking compound-heterozygous variants when trying to identify potentially causal genes in
pediatric disease. In addition, this work provides software tools that are openly available for
other researchers to use; these tools make it easier to phase patient DNA sequence data and to
identify compound-heterozygous variants.

Keywords: compound heterozygous, trios, nuclear families, phasing, pipeline, whole genome
sequencing, pediatric cancer, structural birth defects, compoundHetVIP, trioPhaser
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Abstract
A compound heterozygous (CH) variant is a type of germline variant that occurs when each
parent donates one alternate allele and these alleles are located at different loci within the same
gene. Pathogenic germline variants have been identified for some pediatric cancer types but in
most studies, CH variants are overlooked. Thus, the prevalence of pathogenic CH variants in
most pediatric cancer types is unknown. We identified 26 studies (published between 1999 and
2019) that identified a CH variant in at least one pediatric cancer patient. These studies
encompass 21 cancer types and have collectively identified 25 different genes in which a CH
variant occurred. However, the sequencing methods used and the number of patients and genes
evaluated in each study were highly variable across the studies. In addition, methods for
assessing pathogenicity of CH variants varied widely and were often not reported. In this review,
we discuss technologies and methods for identifying CH variants, provide an overview of studies
that have identified CH variants in pediatric cancer patients, provide insights into future
directions in the field, and give a summary of publicly available pediatric cancer sequencing
data. Although considerable insights have been gained over the last 20 years, much has yet to be
learned about the involvement of CH variants in pediatric cancers. In future studies, larger
sample sizes, more pediatric cancer types, and better pathogenicity assessment and filtering
methods will be needed to move this field forward.
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Introduction
Each year worldwide, ~300,000 children under the age of 14 are diagnosed with cancer (SweetCordero and Biegel, 2019). Since the 1970s, 5-year survival rates for pediatric cancer patients
have steadily increased and are presently over 80% (Phillips et al., 2015). Despite improvements
in treatments and survival rates, the causes of most pediatric cancers are still relatively unknown
(American Cancer Society). Recent large-scale studies have helped elucidate the involvement of
germline mutations in pediatric cancer development. For example, a 2015 study analyzed
mutations across 565 known, cancer-associated genes for 1,120 pediatric cancer patients and
found that 8.5% of the patients had an identifiable, pathogenic germline mutation in at least one
of these genes (Zhang et al., 2015). Similarly, a 2016 study identified 10% of pediatric cancer
patients as having a mutation in a cancer predisposition gene (Parsons et al., 2016). These studies
highlight that heritable predisposition does play a critical role in many pediatric cancer cases
(Dean and Farmer, 2017). However, these studies also emphasize the need to elucidate additional
types of rare, germline variants associated with pediatric cancers. In this review, we focus on
compound heterozygous (CH) variants, a type of germline variant that has been understudied in
pediatric cancers.

CH variants occur when each parent donates one alternate allele and when the alleles are located
at different loci within the same gene (Fig. 1.1) (Kamphans et al., 2013). CH variants are
particularly relevant to certain types of genes, such as tumor suppressors, where most loss-offunction mutations are recessive in nature (Chial, 2008). Tumor suppressor genes are involved in
inhibiting cell division, initiating apoptosis, repairing DNA damage, and suppressing metastasis
(Wang et al., 2018). When tumor suppressor genes lose function, tumors can arise and existing
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tumors can become more aggressive (Guo et al., 2014; Wang et al., 2018). Commonly,
researchers identify cases where two non-reference alleles at a given genomic locus have been
inherited, one from each parent (homozygosity). But in other cases, an individual may inherit
two defective copies of a tumor suppressor gene—one from each parent, with defects at different
loci in the gene—thereby resulting in no functional copies of the tumor suppressor gene and
potentially an increased susceptibility to cancer development (Weinberg, 2013).
Sanger sequencing has classically been used to identify CH variants. In this approach, DNA is
collected from the patient and his/her parents, and visual analysis of an electropherogram helps
to confirm Mendelian inheritance of a CH variant (Piane et al., 2016; Nafisinia et al., 2017).
These technologies are most relevant when the researcher wishes to examine one or a few genes.
In recent years, detection of CH variants at a larger scale has become feasible with the advent of
next-generation sequencing (NGS).

NGS technologies (e.g. Illumina, PacBio) can sequence DNA in a high-throughput manner and
thus allow for the examination of many genes in a single run (Tewhey et al., 2011). In order to
use NGS data for identifying CH variants, sequencing data must be phased. The process of
phasing estimates which chromosome (haplotype) the nucleotides are located on, thereby helping
to distinguish between maternally and paternally inherited variants (Choi et al., 2018). If it is
known before sequencing that haplotype information will be needed, a laboratory-based,
haplotype-estimation method can be used, such as Linked-Read technology by 10X Genomics
(Zheng et al., 2016). This approach uses micro-droplet-based dilution to compartmentalize DNA
in a random manner and uses a high number of distinct barcodes. This method prevents the
partitioned DNA molecules from originating from the same genomic loci. Alternatively, if NGS
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libraries have been prepared without regard to phase, computer-based phasing algorithms can be
used to estimate haplotypes (Browning and Browning, 2007; Delaneau et al., 2013; Loh et al.,
2016). These algorithms estimate a patient’s haplotypes from genotype data after making
inferences from a population-based reference panel and/or inferences from parental inheritance
patterns.

Assessment of CH variant pathogenicity can be accomplished using trusted variant databases,
published literature, functional studies, and predictive algorithms (Richards et al., 2015). While
each assessment method can be useful, each has unique challenges that may lead to poor
pathogenicity assessment. Databases may lack validation data, contain outdated information, or
be based on small sample sizes. Published literature may reflect a poor study design or a limited
sample size. Functional studies aim to understand the downstream effects of genetic variants
(Rodenburg, 2018). For example, gene rescue assays seek to determine whether introducing the
wild-type allele into patient derived cells “rescues” the phenotype. However, functional studies
may not reflect the true biological environment or may not take full pathways into consideration
(Richards et al., 2015). Common variant prediction algorithms, such as SIFT and PolyPhen-2,
use nucleotide sequence homology (among other parameters) to predict whether protein function
is affected by an amino acid substitution (Ng and Henikoff, 2003; Adzhubei et al., 2010).
Predictive algorithms often have low specificity for missense variant prediction (Richards et al.,
2015). Therefore, in most cases, it is important to use multiple programs for pathogenicity
assessment (Niroula and Vihinen, 2019).
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In the following sections, we provide an overview of studies that have identified CH variants in
pediatric-cancer patients, provide insights into future directions in the field, and give a summary
of available pediatric cancer sequencing data.

Methods
Literature Search
On March 20, 2020, we searched PubMed, Google Scholar, and Web of Science for “((pediatric
cancer) OR pediatric tumor OR childhood cancer OR childhood tumor) AND ((compound
heterozygous) OR compound heterozygosity) AND humans AND Journal Article[ptyp]”,
‘(“pediatric cancer” OR “pediatric tumor” OR “childhood cancer” OR “childhood tumor”) AND
(“compound heterozygous” OR "compound heterozygosity")’, and “((pediatric cancer OR
pediatric tumor OR childhood cancer OR childhood tumor) AND (compound heterozygous OR
compound heterozygosity))”, respectively. The above searches were also filtered to be inclusive
of studies published between1999 and 2019. Based on these criteria, 247, 709, and 33 results
were obtained from PubMed, Google Scholar, and Web of Science, respectively. Of the returned
results, we examined each article's abstract (and full article text when necessary) to determine
whether the researchers had identified CH variants in one or more pediatric cancer patients; we
identified 35 total articles that met these criteria (Fig. 1.2).

Evaluation Criteria
We further evaluated the 35 articles to identify whether the authors had used germline tissue for
DNA sequencing and described methods for assessing compound heterozygosity. If germline
tissue was used for sequencing, and if the authors indicated how compound heterozygosity was
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determined, we included the study. Of the 35 studies identified, 26 met these criteria and are
described in this review (Fig. 1.2). For each of the 26 studies, we obtained additional information
such as tumor type, the number of CH variants identified and the genes in which they were
identified, the number of patients per cancer type that were included in the study, how compound
heterozygosity was determined (i.e. whether through Mendelian inheritance or phasing), the type
of sequencing technology used, the use of parental sequence data, and how variant pathogenicity
was evaluated (Supplementary Data 1: T1).

Tumor Type Standardization
To ensure consistency of names used to describe the tumor types and to reduce the total number
of tumor types to consider, we standardized tumor type names, when possible, using parent terms
defined in the National Cancer Institute Thesaurus (Sioutos et al., 2007). For example, we
grouped B-cell acute lymphoblastic leukemia and T-cell acute lymphoblastic leukemia under
their parent term, ‘acute lymphoblastic leukemia’ (ALL).

Variant Pathogenicity Reassessment and Cancer Pathway Association
Because pathogenicity estimation methods varied widely across the studies and because it had
been many years since some articles were published, we reassessed pathogenicity using ClinVar
and Variant Effect Predictor (VEP) for all studies that provided variant positions (McLaren et al.,
2016; Landrum et al., 2018). We used Kyoto Encyclopedia of Genes and Genomes (KEGG) to
determine which of the genes, across all studies, are in a known cancer pathway. We used
Catalogue of Somatic Mutations in Cancer (COSMIC) to identify genes with known cancer
associations (Kanehisa and Goto, 2000; Tate et al., 2019).
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Results
Overview of Pediatric Cancer Types and Genes Studied
Researchers have identified CH variants across many pediatric cancer types, even though
relatively few articles on these topics have been published overall. From 1999 until 2019, an
average of ~1.2 journal articles per year were published on CH variant discovery across a total of
21 cancer types (Supplementary Data 1: T1); the highest number (n = 7) were published in 2018.
The cancer types studied most frequently were ALL (5 publications) (Valentine et al., 2014;
Spinella et al., 2015; Moriyama et al., 2017; Diets et al., 2018; Sharapova et al., 2018), nonHodgkin's Lymphoma (4 publications) (Østergaard et al., 2005; Peters et al., 2009; Bakry et al.,
2014; Diets et al., 2018), and medulloblastoma (4 publications) (Svojgr et al., 2016; Gröbner et
al., 2018; Waszak et al., 2018; Schieffer et al., 2019) (Fig. 1.3). ALL and non-Hodgkin's
lymphoma are both blood-based cancers, while medulloblastoma is a type of brain tumor
(Sandlund et al., 1996; Hunger and Mullighan, 2015; Kumar et al., 2015). In addition, six
publications described a patient having been diagnosed with two or more cancer types, which
include: glioblastoma + non-Hodgkin's Lymphoma + oligodendroglioma (Bakry et al., 2014),
glioblastoma + rectal carcinoma (Bakry et al., 2014), glioblastoma + non-Hodgkin's lymphoma
(Chmara et al., 2013), ALL + rectal adenoma (Herkert et al., 2011), acute myeloid leukemia
(AML) + medulloblastoma (Scott et al., 2007), colon carcinoma + oligodendroglioma (De Rosa
et al., 2000), and brain tumor + rhabdomyosarcoma (Quesnel et al., 1999) (Fig. 1.3).

Sample sizes were limited in most studies (Table 1.1). Only ~19% of the studies had a sample
size greater than 10 for one or more cancer types (Valentine et al., 2014; Zhang et al., 2015;
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Diets et al., 2018; Gröbner et al., 2018; Waszak et al., 2018). Across all studies, cancer types
with more than 10 samples included AML, ALL, high-grade glioma, medulloblastoma
(Valentine et al., 2014; Zhang et al., 2015; Diets et al., 2018; Gröbner et al., 2018). 13 studies
evaluated a single patient (Quesnel et al., 1999; De Rosa et al., 2000; Okkels et al., 2006; Scott et
al., 2007; Peters et al., 2009; Majumdar et al., 2010; Chmara et al., 2013; Piane et al., 2016;
Diness et al., 2018; Salih et al., 2018; Sharapova et al., 2018; Maciaszek et al., 2019; Schieffer et
al., 2019).

Across all studies, at least one CH variant was identified in 25 genes (Table 1.1). Of these genes,
7 are known to be associated with hereditary cancer predisposition (Table 1.2). The remaining 18
genes may provide clues about alternative mechanisms of cancer predisposition. For example,
one study identified 6 ALL and 13 AML patients with a CH variant in KMT2C (Valentine et al.,
2014), and one study identified two hepatoblastoma patients with a CH variant in MUC4 (Zhang
et al., 2018). DNA alterations in KMT2C and MUC4 have been observed in the somatic tissue of
medulloblastoma and head and neck squamous cell carcinoma patients, respectively (Tate et al.,
2019). Therefore, future studies may reveal that germline mutations in these genes also
contribute to pediatric cancer predisposition.

Overview of Studies That Identified CH Variants in Genes Associated with Pediatric Cancers
Here we provide an overview of CH variant findings specific to genes that have a known
association to cancer predisposition. Of the 25 characterized genes identified across all studies
(Table 1.1), COSMIC classifies 7 as being associated with hereditary predisposition for at least
one type of pediatric cancer: ATM, BRCA2, MSH6, PMS2, RECQL4, SDHB, and TP53 (Table
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1.2). Below we provide insight about the functions of these genes, prior associations that have
been made for non-compound germline variants, and CH variants in these genes.

ATM, BRCA2, and SDHB are known tumor suppressor genes. Non-compound germline
variations in these genes have been associated with leukemias, lymphomas, medulloblastomas,
and gliomas (Table 1.2). Similarly, CH variants in ATM have been observed in ALL,
astrocytoma, and high-grade glioma (Zhang et al., 2015; Piane et al., 2016; Sharapova et al.,
2018). BRCA2 plays important roles in DNA repair, and germline variations in this gene have
been associated with breast cancer, ovarian cancer, pancreatic cancer, and leukemia risk
(Kanehisa and Goto, 2000; Tate et al., 2019) (Table 1.2). To date, CH variants in BRCA2 have
been observed in medulloblastomas and Wilms tumors (Svojgr et al., 2016; Gröbner et al., 2018;
Waszak et al., 2018). Variations in SDHB have been associated with paraganglioma and
pheochromocytoma (Table 1.2); one patient with paraganglioma had a CH variant in this gene
(Majumdar et al., 2010).

MSH6 and PMS2 are both considered to be tumor-suppressor and mismatch repair (MMR) genes
(Ripperger and Schlegelberger, 2016; Tabori et al., 2017; Tate et al., 2019). Patients with
biallelic germline mutations in an MMR gene (MLH1, MSH2, MSH6, and PMS2) are considered
to have a syndrome known as constitutional mismatch repair disease (CMMRD) (Ripperger and
Schlegelberger, 2016; Tabori et al., 2017). Germline mutations in MMR genes have been
associated with a predisposition to many different types of cancer (Table 1.2) (Tabori et al.,
2017), including hematological malignancies, brain tumors, and digestive tract cancers
(Ripperger and Schlegelberger, 2016). To date, CH variants in MSH6 have been identified in
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patients with high-grade glioma, non-Hodgkin’s lymphoma, glioblastoma, medulloblastoma,
AML, or colorectal cancer (Østergaard et al., 2005; Okkels et al., 2006; Scott et al., 2007; Peters
et al., 2009; Bakry et al., 2014; Gröbner et al., 2018). PMS2 CH variants have been identified in
high-grade glioma, non-Hodgkin’s lymphoma, glioblastoma, oligodendroglioma, rectal cancer,
colon adenoma, ALL, recta adenoma, neuroepithelial neoplasm, astrocytoma, and colon
carcinoma (De Rosa et al., 2000; Herkert et al., 2011; Leenen et al., 2011; Chmara et al., 2013;
Bakry et al., 2014; Gröbner et al., 2018).

RECQL4 and TP53 both have more than one role in cancer (Tate et al., 2019). RECQL4 is
involved in many intracellular regulatory pathways and can act either as an oncogene or a tumor
suppressor gene (Kellermayer, 2006; Arora et al., 2016). Germline cancer associations for
RECQL4 include osteosarcoma, skin basal cell, and skin squamous cell (Table 1.2). CH variants
in RECQL4 have been associated with osteosarcoma in two studies (Salih et al., 2018; Maciaszek
et al., 2019). TP53 is involved in many cancer pathways, and germline variation in this gene has
been associated with a wide range of tumor types (Table 1.2). One patient with
rhabdomyosarcoma + brain tumor had a CH variant in TP53 (Quesnel et al., 1999).

Methodologies Used to Identify CH Variants and Assess Pathogenicity
The sequencing methods used were highly variable across the studies (Table 1.3 and
Supplementary Data 1:T1). Of the studies in this review, 10 indicated that they used one or more
forms of NGS sequencing (whole-exome, whole-genome, RNA-seq) and thus were able to
sample CH variants broadly (Valentine et al., 2014; Spinella et al., 2015; Zhang et al., 2015,
2018; Diets et al., 2018; Diness et al., 2018; Gröbner et al., 2018; Waszak et al., 2018;
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Maciaszek et al., 2019; Schieffer et al., 2019). 13 studies indicated that they used non-NGS
methods (Sanger, Direct sequencing, SNP-array, Multiplex ligation-dependent probe
amplification) and were therefore limited in the number of genes and CH variants analyzed
(Quesnel et al., 1999; De Rosa et al., 2000; Østergaard et al., 2005; Okkels et al., 2006; Scott et
al., 2007; Herkert et al., 2011; Leenen et al., 2011; Chmara et al., 2013; Bakry et al., 2014; Piane
et al., 2016; Svojgr et al., 2016; Moriyama et al., 2017; Sharapova et al., 2018). Three
clinical/case report studies did not describe the exact DNA sequencing technology used (Peters
et al., 2009; Majumdar et al., 2010; Salih et al., 2018); however, we inferred that Sanger
sequencing was inferred in these three studies because single genes were the focus of the studies,
parent DNA was also sequenced, and DNA variant locations were provided by the authors.

Across all studies, the methodology used to estimate haplotypes varied considerably (Table 1.3
and Supplementary Data 1:T1). Four of the studies used a computer-based phasing algorithm to
estimate haplotypes (Zhang et al., 2015; Moriyama et al., 2017; Gröbner et al., 2018; Waszak et
al., 2018). One study used evidence from RNA-seq data that the alternate alleles were on
different chromosomes (Zhang et al., 2015). All other studies that performed phasing used
sequence data from the patient and his/her parent(s) (i.e. Mendelian inheritance) (Quesnel et al.,
1999; De Rosa et al., 2000; Okkels et al., 2006; Scott et al., 2007; Peters et al., 2009; Majumdar
et al., 2010; Herkert et al., 2011; Leenen et al., 2011; Chmara et al., 2013; Bakry et al., 2014;
Valentine et al., 2014; Spinella et al., 2015; Piane et al., 2016; Svojgr et al., 2016; Diets et al.,
2018; Diness et al., 2018; Salih et al., 2018; Sharapova et al., 2018; Zhang et al., 2018;
Maciaszek et al., 2019; Schieffer et al., 2019).
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The methods used to classify variant pathogenicity also varied widely from study to study (Table
1.3 and Supplementary Data 1:T1). Eight studies used predictive algorithms as the sole means of
pathogenicity assessment (Herkert et al., 2011; Bakry et al., 2014; Spinella et al., 2015; Piane et
al., 2016; Diets et al., 2018; Gröbner et al., 2018; Sharapova et al., 2018; Waszak et al., 2018).
Four studies used guidelines set forth by the American College of Medical Genetics and
Genomics (ACMG) and the Association for Molecular Pathology (AMP) (Zhang et al., 2015,
2018; Maciaszek et al., 2019; Schieffer et al., 2019). Two studies used literature searches to look
for known effects of the identified variants (Scott et al., 2007; Leenen et al., 2011). Two studies
analyzed RNA expression of altered alleles (Quesnel et al., 1999; Diness et al., 2018). One study
did not directly assess pathogenicity; rather they reported on variants that met specific criteria
such as the variant being a nonsynonymous substitution (Valentine et al., 2014). Nine studies
made no mention of assessing CH variant pathogenicity (De Rosa et al., 2000; Østergaard et al.,
2005; Okkels et al., 2006; Peters et al., 2009; Majumdar et al., 2010; Chmara et al., 2013; Svojgr
et al., 2016; Moriyama et al., 2017; Salih et al., 2018).

There were a total of 18 CH variants where both alleles were reported as pathogenic or likely
pathogenic by the authors of the study (Supplementary Data 1: T2). Because some of the studies
were conducted years ago and pathogenicity classifications may have been updated, we reassessed the pathogenicity of all variants that were provided by the authors of the studies. Using
ClinVar and VEP (as SIFT and PolyPhen scores), we were able to confirm pathogenicity for 5 of
the 18 CH variants with one or more of our reassessment methods (Supplementary Data 1:T2).
These confirmed variants were in MYO18B (Schieffer et al., 2019), BRCA2 (Waszak et al.,
2018), FAM83H (Diets et al., 2018), and HIST1H1C (Diets et al., 2018). In addition, we were
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able to classify 3 CH variants as pathogenic or likely pathogenic that were not indicated as such
in the original study. These variants were in RECQL4 (Salih et al., 2018), PMS2 (Herkert et al.,
2011), and MSH6 (Scott et al., 2007). For the remaining variants, either only one allele from a
CH pair was able to be classified, or no information was available in the databases
(Supplementary Data 1:T2).

Discussion
Observations and Future Directions
Research to date has highlighted that CH variants are observed relatively rarely but occur in
many different genes and a diverse array of pediatric tumor types. However, our knowledge of
the roles that CH variants play in pediatric cancers is only in its infancy. Prior studies have
focused primarily on candidate genes, have been limited to individual cancer types, or have been
limited by small sample sizes (Table 1.1). Due to these issues, important CH variants may have
been missed. For example, in AML, tumor suppressor genes that are known to harbor germline
risk variants include BRIP1, FANCA, FANCC, FANCD2, FANCE, FANCF, FANCG, PALB2,
and SBDS (Sondka et al., 2018; Tate et al., 2019). However, no study to date has found CH
variants in any of these genes for AML patients. Similarly, ATM, NBN, PALB2, PMS2, PTCH1,
and SUFU are tumor suppressor and germline risk genes for medulloblastoma, but CH variants
in these genes have not been found in prior studies.

One factor that may have contributed to a lack of identifying CH variants in known cancerpredisposition genes may be filtering based on minor allele frequencies (MAF). Commonly,
individual alleles with a MAF >1% (or >0.5%) in a control population are excluded from
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analyses because they are assumed to have benign effects (Richards et al., 2015; Niroula and
Vihinen, 2019). Yet, this traditional filtering criterion may be too stringent for identifying
pathogenic CH variants. By definition, two pathogenic alleles must be present for a recessive
phenotype to manifest itself. Suppose, for example, that one allele in a given gene is relatively
rare, having been observed in 0.8% of the population. Now suppose that a second allele is
present at a different locus within the same gene and that this allele has a population prevalence
of 5%. MAF filtering considers each locus separately, so the latter variant would be excluded by
the 1% threshold, causing this potentially pathogenic CH variant to be overlooked. Assuming
non-consanguinity and using the probability multiplication rule, the population prevalence of this
particular CH variant would be estimated at approximately 0.04% (5% x 0.8%). Although care
must be taken to consider other possible combinations of in trans alleles in this gene (Eilbeck et
al., 2017), this example illustrates that traditional MAF filtering may be too simplistic for CH
variant analysis. Furthermore, researchers must account for any homozygous, non-reference
genotypes that have been observed for either allele in healthy individuals (Kamphans et al.,
2013).

Further complicating matters, it is difficult to estimate the a priori expectation of finding a CH
variant in a given gene. The longer a gene, the higher the probability that two pathogenic alleles
will occur within that gene. Accordingly, genome-wide studies may be biased toward identifying
CH variants in longer genes. For example, across the 26 studies covered in this review, the
average coding sequence (CDS) length for genes with an identified CH variant was 5,610 bases
(median: 3,591 bases) (Table 1.2). Comparatively, using data from GENCODE, we calculated
the average CDS length of protein coding genes across the human genome to be ~1,796 bases
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(median: 1,338) (Frankish et al., 2019). Efforts should be made to help alleviate this bias and
other confounding factors. For example, Itan, et al. developed the Gene Damage Index to
prioritize genes based on CDS length, protein complexity, paralog count, and evolutionary
pressures (Itan et al., 2015). When prioritizing CH variants at the gene level in this way, the
number of false-positive genes may be reduced.

Data Availability
The future is primed for more rapid discovery of genetic factors involved in pediatric cancers
and a clearer understanding of the roles that CH variants play in pediatric cancer development
and progression. Publicly available data are becoming readily accessible for researchers to study,
and more data will become available over the next few years. For example, the NIH-funded
Gabriella Miller Kids First (GMKF) initiative is sequencing germline DNA from hundreds of
trios (affected child and both parents). This initiative is enabling researchers to obtain Illuminabased, whole-genome sequencing (WGS) data for these trios across many childhood cancer types
(and other pediatric diseases) (Gabriella Miller Kids First Pediatric Research Program).
Currently, the GMKF repository contains sequencing data for Ewing sarcoma (250 trios) and
neuroblastoma (470 trios). In the coming years, the GMKF repository is expected to include data
from pediatric cancers such as osteosarcoma, leukemia, enchondromatosis, brain tumors,
myeloid malignancies, and others. This repository will prove valuable as parental data may allow
for better identification of CH variants and de novo mutations (Francioli et al., 2017; Choi et al.,
2018).
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Frequently it is infeasible to obtain sequencing data from a proband's parents due to cost
limitations or logistical challenges (a parent may not consent to participate or may be
unavailable, a parent may be deceased, the child may be adopted, etc.). Projects such as
Therapeutically Applicable Research To Generate Effective Treatments (TARGET), St. Jude
Cloud, and the Children's Brain Tumor Tissue Consortium (CBTTC) have sequenced DNA for
thousands of patients across many pediatric diseases, but sequencing data are available for the
proband only in these resources (Children’s Hospital of Philadelphia; Downing et al., 2012;
Office of Cancer Genomics, 2013). At the time of this writing, TARGET included matched
tumor-normal, multi-omic data across six types of pediatric cancer, including AML (n ≈ 50),
neuroblastoma (n ≈ 228), Wilms tumor (n ≈ 81), osteosarcoma (n ≈ 89), clear cell sarcoma of the
kidney (n ≈ 13), and rhabdoid tumor (n = 43) (Office of Cancer Genomics, 2013). The St. Jude
Cloud contained matched tumor-normal data for ~42 pediatric cancer types/subtypes, which
encompassed ~2,168 patients (Downing et al., 2012). Some of the datasets with the highest
number of patients in the St. Jude Cloud included ALL (n ≈ 260), AML (n ≈ 189), HGG (n ≈
163), and neuroblastoma (n ≈ 135)(Downing et al., 2012). Eight cancer types are represented by
over 100 patients, while 14 cancer types had data for 10 or fewer patients. The CBTCC is a
collaborative effort dedicated to the study and treatment of pediatric brain tumors (Children’s
Hospital of Philadelphia). At the time of this writing, CBTCC included genomic data for ~871
patients across ~38 pediatric brain tumor types. Although these databases do not contain parental
genome data, computer-based algorithms can often determine a variant's parent-of-origin using
haplotype reference panels (Browning and Browning, 2011).
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Thanks to these public and nonprofit efforts, we have entered an era in which researchers can
shed more light on the genes and pathways that influence specific pediatric cancers through the
use of genome-wide, publicly available data. We advocate that researchers take advantage of
these resources.

Conclusion
Many discoveries about CH variants and their association with pediatric cancers have been made
over the last 20 years; the role of CH variants in cancer and developmental pathways and the
prevalence of these variants in pediatric cancers are beginning to be uncovered. Through the
works discussed in this review, much insight has been gained. As future studies are conducted on
CH variants in pediatric cancers, we anticipate that CH variants will play a more prominent role
in elucidating disease mechanisms. This heightened knowledge could expand this field of study
and eventually lead to the development of targeted treatments. Furthermore, having an
understanding of CH variants and their role in disease development could prove beneficial for
disease monitoring. For example, a child with a malignancy who has a germline risk variant in a
known predisposition gene and/or key pathway could be more regularly monitored and assessed
for additional tumor development (Milanese and Wang, 2019). If risk variants are in genes
associated with one particular type of cancer, screening efforts could be more directed than
general cancer screening. More specific screening could allow for earlier detection of tumors,
sooner treatments, and prophylactic measures. Finally, a heightened knowledge of CH variants
could lead to an expansion of our understanding of other pediatric diseases, such as birth defects,
and even inherited disorders that arise in adults.
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Tables and Figures
Chapter 1 Tables
Table 1.1. Genes with identified CH variants and the study(-ies) that identified them. The
details in parentheses next to the author name indicate the cancer type(s) associated with each
CH variant, the number of patients evaluated in the study, and the number of patients who had a
CH variant in that gene. For example, Valentine, et al. evaluated 13 AML patients and identified
a CH variant in all 13 patients for the ANKRD36 gene. AML = acute myeloid leukemia, ALL =
acute lymphoblastic leukemia, HGG = high-grade glioma, MB = medulloblastoma, WT = Wilms
tumor, HB = hepatoblastoma, NHL = non-Hodgkin’s lymphoma, GB = glioblastoma, NN =
neuroepithelial neoplasm, and OS = osteosarcoma.

Gene

Study(-ies)

ANKRD36 Valentine, et al. (AML: 13/13)
ATM

Sharapova, et al. (ALL: 1/1); Piane, et al. (astrocytoma: 1/1); Zhang, et al. (2015)
(HGG: 1/99)

BRCA2

Waszak, et al. (MB: 4/1022); Gröbner, et al. (MB: 1/42); Svojgr, et al. (WT: 1/1,
MB: 1/1)

CEP55

Spinella, et al. (ALL: 2/2)

DDX41

Diness, et al. (myeloid neoplasm: 1/1)

DNAH2

Spinella, et al. (ALL: 2/2)

ENOSF1

Zhang, et al. (2018) (HB: 2/2)

FAM83H

Diets, et al. (ALL: 1/13)

FLG

Valentine, et al. (AML: 3/13)

GRIK1

Diets, et al. (ALL: 1/13)

H1-2

Diets, et al. (NHL: 1/3)

IRF5

Diets, et al. (WT: 1/1)

KMT2C

Valentine, et al. (ALL: 6/12; AML: 13/13)

MSH6

Gröbner, et al. (HGG: 2/67); Bakry, et al. (NHL: 1/5; GB: 1/8); Peters, et al.
(NHL: 1/1); Scott, et al. (MB + AML: 1/1); Okkels, et al. (colorectal: 1/1);
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Østergaard, et al. (NHL: 1/1; GB: 1/1);
MUC4

Zhang, et al. (2018) (HB: 2/2)

MYO18B

Schieffer, et al. (MB: 1/1)

NUDT15

Moriyama, et al. (ALL: 1/5)

PDE4DIP

Spinella, et al. (ALL: 2/2)

PMS2

Gröbner, et al. (HGG: 1/67); Bakry, et al. (NHL: 1/5; NHL + GB +
oligodendroglioma: 1/1; rectal cancer + GB: 1/1); Chmara, et al. (GB + NHL: 1/1);
Herkert, et al. (colon adenoma: 1/1; ALL + rectal adenoma: 1/1); Leenen, et al.
(NN: 1/1; astrocytoma: 1/1); De Rosa, et al. (oligodendroglioma + colon
carcinoma: 1/1)

RBMX

Valentine, et al. (ALL: 6/12)

RECQL4

Maciaszek, et al. (OS: 1/1); Salih, et al. (OS: 1/1)

RYR1

Valentine, et al. (AML: 9/13)

SDHB

Majumdar, et al. (paraganglioma: 1/1)

SLX4

Spinella, et al. (ALL: 2/2)

TP53

Quesnel, et al. (rhabdomyosarcoma + brain tumor: 1/1)
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Table 1.2. Details of genes with identified CH variants. The average CDS gene length across
all studies was 5,610, and the average total gene length was 95,022. ATM, BRCA2, MSH6,
PMS2, RECQL4, SDHB, and TP53 are all associated with germline tumor types and are known
tumor suppressor genes as classified by COSMIC. BRCA2, MSH6, and TP53 are all part of a
cancer pathway as classified by KEGG. A value of "-" indicates that an association was not
observed. TSG = tumor suppressor gene.

Gene
ANKRD36

ATM

Gene CDS Total Gene Cancer Pathway Germline Tumor
Length
Length
(KEGG)
Types (COSMIC)
5,678

9,272

Role in Cancer
(COSMIC)

151,216 -

-

-

146,618 -

leukemia;
lymphoma;
medulloblastoma;
glioma

TSG

85,180 yes

breast; ovarian;
pancreatic; leukemia TSG

1,454

32,480 -

-

-

DDX41

1,802

5,384 -

-

-

DNAH2

13,320

116,390 -

-

-

ENOSF1

1,337

42,344 -

-

-

FAM83H

5,192

14,301 -

-

-

12,181

23,074 -

-

-

2,887

403,100 -

-

-

H1-2

638

641 -

-

-

IRF5

1,493

12,581 -

-

-

15,426

301,083 -

-

TSG

colorectal;
endometrial; ovarian TSG

BRCA2

10,415

CEP55

FLG
GRIK1

KMT2C
MSH6

3,591

114,571 yes

MUC4

10,911

65,208 -

-

oncogene

MYO18B

7,889

288,897 -

-

-

NUDT15

489

9,495 -

-

-

7,104

240,105 -

-

fusion

PDE4DIP
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PMS2

2,463

38,181 -

colorectal;
endometrial; ovarian;
medulloblastoma;
glioma
TSG

RBMX

1,166

32,760 -

-

-

osteosarcoma; skin
basal cell; skin
squamous cell

oncogene; TSG

-

-

RECQL4

3,252

6,557 -

RYR1

14,835

153,873 -

SDHB

778

35,310 -

paraganglioma;
pheochromocytoma

TSG

5,488

30,425 -

-

-

25,771 yes

breast; sarcoma;
adrenocortical
carcinoma; glioma;
multiple other tumor oncogene;
types
TSG; fusion

SLX4

TP53

1,194

32

Table 1.3. Methods used by each study for identification and evaluation of CH variants. A
value of "-" indicates that no clear description was provided by the authors. WGS = whole
genome sequencing, WES = whole exome sequencing, MLPA = Multiplex Ligation-dependent
Probe Amplification.
How CH Variant
Identified

Post Sequencing Pathogenicity
Evaluation Criteria

Mendelian Inheritance

ACMG/AMP guidelines

WES, Sanger Mendelian Inheritance

ACMG/AMP guidelines

Zhang, et al.
(2018)

WGS

Mendelian Inheritance

SIFT, PolyPhen-2, MutationTaster
(Schwarz et al., 2014), M-CAP, and
AMP/ACMG guidelines

Diness, et al.
(2018)

WES

Mendelian Inheritance

CADD (Kircher et al., 2014), gene
expression analysis

Mendelian Inheritance

PolyPhen-2

Authors

Sequencing
Technology

Maciaszek, et al.
(2019)
WGS
Schieffer, et al.
(2019)

Sharapova, et al.
(2018)
Sanger

Waszak, et al.
(2018)

Multiple sites within the
same gene were phased
with paired-end RNA
sequencing data and
individual sites were
merged to calculate
WGS, WES, haplotype-specific
RNA-seq
expression ratios.
ClinVar

Diets, et al.
(2018)

WES

Mendelian Inheritance

Gröbner, et al.
(2018)

WGS, WES

Used Platypus which is
a haplotype-based
variant caller (Rimmer CADD, Mutation Assessor (Reva et
et al., 2014)
al., 2011)

Salih, et al.
(2018)

Sanger
(inferred)

Mendelian Inheritance

-

Sanger

PHASE was used to
infer haplotypes
(Stephens and Scheet,
2005)

-

Moriyama, et al.
(2017)
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SIFT, PolyPhen2, CADD

Svojgr, et al.
(2016)

SNP-array

Mendelian Inheritance

-

Piane, et al.
(2016)

Sanger

Mendelian Inheritance

SIFT, Polyphen, MutationTaster

Mendelian Inheritance

SIFT, PolyPhen-2, and hidden
Markov models

Spinella, et al.
(2015)

WES

Zhang, et al.
(2015)

ACMG/AMP guidelines, genetic
databases, medical literature,
Used RNA-seq data to computational predictions, and
WGS, WES, determine CH nature of second hits identified in the tumor
RNA-seq
variant
genome

Valentine, et al.
(2014)

WES

Mendelian Inheritance

Filtered for functional consequences
(e.g. non-synonymous and coding)

Bakry, et al.
(2014)

Sanger

Mendelian Inheritance

Algorithms to predict RNA/protein
disruption

Chmara, et al.
(2013)

Direct
Sequencing,
MLPA

Mendelian Inheritance

-

Herkert, et al.
(2011)

Direct
Sequencing,
MLPA

Mendelian Inheritance

SIFT, AlignGVGD (Tavtigian et al.,
2008), PolyPhen-2, and RNA splice
site prediction programs

Majumdar, et al.
(2010)

Sanger
(inferred)

Mendelian Inheritance

-

Leenen, et al.
(2010)

Sanger

Mendelian Inheritance

Literature search

Peters, et al.
(2009)

Sanger
(inferred)

Mendelian Inheritance

-

Scott, et al.
(2007)

Sanger

Mendelian Inheritance

Literature search

Okkels, et al.
(2006)

Sanger

Mendelian Inheritance

-

Østergaard, et al.
(2005)
Sanger

Mendelian Inheritance

-

De Rosa, et al.
(2000)

Sanger

Mendelian Inheritance

-

Quesnel, et al.
(1999)

Sanger

Mendelian Inheritance

mRNA assay
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Chapter 1 Figures

Figure 1.1. Illustration of compound heterozygous variants. Compound heterozygous
variants occur when a child has an alternate allele from each parent and the variant is located at
different loci within the same gene.
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Figure 1.2. Flow diagram of how the studies in this review were identified. 26 articles met
the evaluation criteria.
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Figure 1.3. The number of publications per cancer type pertaining to CH variants in
pediatric cancer. The literature on CH variants has covered a wide range of cancer types,
especially acute lymphoblastic leukemia, non-Hodgkin's lymphoma, and medulloblastoma. In
six publications, at least one patient was diagnosed with more than one cancer type. These "2+
diagnoses" include patients with the following cancer types: glioblastoma + non-Hodgkin's
Lymphoma + oligodendroglioma (Bakry et al., 2014), glioblastoma + rectal carcinoma (Bakry et
al., 2014), glioblastoma + non-Hodgkin's lymphoma (Chmara et al., 2013) or ALL + rectal
adenoma (Herkert et al., 2011), acute myeloid leukemia + medulloblastoma (Scott et al., 2007),
colon carcinoma + oligodendroglioma (De Rosa et al., 2000), brain tumor + rhabdomyosarcoma
(Quesnel et al., 1999).
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Abstract
Compound Heterozygous (CH) variant identification requires distinguishing maternally from
paternally derived nucleotides, a process that requires numerous computational tools. Using such
tools often introduces unforeseen challenges such as installation procedures that are operatingsystem specific, software dependencies that must be installed, and formatting requirements for
input files. To overcome these challenges, we developed Compound Heterozygous Variant
Identification Pipeline (CompoundHetVIP), which uses a single Docker image to encapsulate
commonly used software tools for file aggregation (BCFtools or GATK4), VCF liftover (Picard
Tools), joint-genotyping (GATK4), file conversion (Plink2), phasing (SHAPEIT2, Beagle,
and/or Eagle2), variant normalization (vt tools), annotation (SnpEff), relational database
generation (GEMINI), and identification of CH, homozygous alternate, and de novo variants in a
series of 13 steps. To begin using our tool, researchers need only install the Docker engine and
download the CompoundHetVIP Docker image. The tools provided in CompoundHetVIP,
subject to the limitations of the underlying software, can be applied to whole-genome, wholeexome, or targeted exome sequencing data of individual samples or trios (a child and both
parents), using VCF or gVCF files as initial input. Each step of the pipeline produces an
analysis-ready output file that can be further evaluated. To illustrate its use, we applied
CompoundHetVIP to data from a publicly available Ashkenazim trio and identified two genes
with a candidate CH variant and two genes with a candidate homozygous alternate variant after
filtering based on user-set thresholds for global minor allele frequency, Combined Annotation
Dependent Depletion, and Gene Damage Index. While this example uses genomic data from a
healthy child, we anticipate that most researchers will use CompoundHetVIP to uncover missing
heritability in human diseases and other phenotypes. CompoundHetVIP is open-source software
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and can be found at https://github.com/dmiller903/CompoundHetVIP; this repository also
provides detailed, step-by-step examples.
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Introduction
A compound heterozygous (CH) variant occurs when a person inherits two alleles, one from
each parent, and these alleles are located at different positions within the same gene1 . The
compound effects of these alternate alleles may lead to phenotypic effects as seen in some cases
of human disease, including ataxia telangiectasia, NGLY1 deficiency, and various types of
pediatric cancer2– 4 . For example, CH variants in the mismatch repair gene, MSH6, have been
identified in pediatric patients with colorectal cancer, medulloblastoma, high-grade glioma,
glioblastoma, non-Hodgkin’s lymphoma, and acute lymphoblastic leukemia4 . To detect CH
variants in next-generation sequencing data, it is necessary to differentiate between paternally
and maternally derived nucleotides1 . Laboratory-based methods such as fosmid-pool-based or
linked-read sequencing can be used; however, if DNA libraries are prepared and sequenced
without regard to nucleotide inheritance (as is done in most sequencing projects), computational
methods can help determine parental inheritance through haplotype estimation (“phasing”)5– 7 .
Available phasing tools require specific input file types (such as VCF or Plink files) and
reference files which are not standardized across different phasing software. In addition, many
phasing programs require that input files have been aligned to a specific reference genome, do
not contain multiallelic positions, are free of repeat positions, and that each chromosome be
phased separately8– 10 . Figuring out how to prepare files for phasing can be challenging as
passing files from program to program may result in unforeseen incompatibilities. Additionally,
installing some programs can be challenging because of operating-system specific installation
processes and software dependencies.
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We have designed Compound Heterozygous Variant Identification Pipeline (CompoundHetVIP)
to help researchers overcome these time-consuming challenges when identifying CH variants.
CompoundHetVIP encapsulates specific versions of existing tools, required software
dependencies, and custom Python scripts into a cohesive computational environment packaged
as a Docker image 11 . Accordingly, researchers need only install the Docker software and
download the CompoundHetVIP Docker image to begin performing CH, homozygous alternate,
and de novo analyses at the command line. Furthermore, because the source code for
CompoundHetVIP is publicly available, other researchers will be able to reproduce the analyses
and investigate the specific methodologies used.

Methods
Implementation
The functionality of CompoundHetVIP is divided into a series of 13 steps (Fig. 2.1). For each
step, a Python script is executed within a Docker container. These scripts provide logic for
processing data files and invoking third-party tools. By breaking the pipeline into 13 steps, users
have flexibility to perform the steps that are most relevant to their analysis. For example,
researchers can use input data for an affected individual only or for a trio (an affected individual
and both parents). If parental data are unavailable and the variant positions within the VCF file
correspond to genome build GRCh37, users may skip the first three steps. A detailed, step-bystep guide is available on GitHub and as Extended data12 .

Workflow
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For step 1, the inputs can be either Variant Call Format (VCF)13 or gVCF14 files that were
generated from whole-genome, whole-exome, or targeted exome sequencing data. VCF files
contain variant sites only, whereas gVCF files include non-variant sites, too. For each parent of a
trio being evaluated, our script retains nucleotide positions that are in common with the child.
When gVCF files are used (whether for trios or individuals), our script removes all non-variant
sites for the child (but retains these for the parents to support determination of CH status). When
applied to trio data, some phasing tools, such as SHAPEIT2 8 , require a single input file for each
trio. Therefore, in step 2 (used only when working with trios), we combine the variant files for
each member of a trio into a single VCF file using either BCFtools (VCF input files)15 or GATK4
(gVCF input files)14 . If GATK4 is used, joint-genotyping is also performed on the trio VCF.

The remaining steps can be applied either to trios or individuals. Some phasing and annotation
programs require that data be aligned to genome build GRCh37; thus, we use this reference
genome as our standard. For variant files that have been aligned to genome build GRCh38, step
3 uses Picard Tools16 to convert the data to GRCh37 positions using a liftover process. During
liftover, some sites may be present in GRCh38, but their exact position in GRCh37 is unknown.
To avoid ambiguity, these sites are removed during step 4. This step also removes positions that
are multiallelic or duplicated to maintain compatibility with programs such as Plink217, 18 and
SHAPEIT2 (used in steps 5 and 6, respectively). For trio VCF files, sites that contain missing
genotype information (i.e. "./.") for both parents are removed to improve phasing accuracy.

CompoundHetVIP can perform phasing using SHAPEIT2, Eagle210 , and/or Beagle9 . Each of
these programs requires that each chromosome be phased independently. Additionally, when
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using SHAPEIT2, it is recommended that PLINK files (.bed, .bim, .fam) be used as input for
phasing. Therefore, step 5 divides a VCF file by chromosome into multiple files and creates the
necessary PLINK files for each chromosome (when SHAPEIT2 is used for phasing).

Step 6 phases the variants in each chromosome using default parameters for the phasing program
chosen by the user. We recommend using SHAPEIT2 because it can applied either to trios or
individuals. When parents’ genotypes are available, this program uses Mendelian logic for
phasing and a population-based haplotyped reference panel when the phase of the child cannot
be determined from Mendelian logic alone (i.e. both parents and child are heterozygous). In
addition, if a parent is missing genotype information at a position, SHAPEIT2 imputes the
missing information. All supported phasing programs integrate the 1000 Genomes Project phase
3 haplotype reference panel19 and do not require sequence alignment files (.bam), such as those
required by read-based programs20, 21 . In some scenarios, SHAPEIT2 switches the REF and ALT
alleles. Therefore, step 7 ensures that the REF/ALT alleles of the phased VCF files are
congruent with those of the reference genome. Also, sites with Mendelian errors are removed.

To make subsequent analysis of the phased files easier, step 8 concatenates all phased
chromosomes into a single file. If a user is analyzing multiple trios (or individuals), this script
can also merge the data for these trios (or individuals) into a single VCF file.

Step 9 normalizes VCF files as recommended by GEMINI22 (used in step 11). Normalization
involves left-alignment and trimming of variants23 . This process helps ensure that variants are
represented at their left-most position, with as few nucleotides as possible, and unambiguously.
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This step uses vt tools23 . In step 10, SnpEf 24 provides information about the effects of variants
on function for known genes. Then, in step 11, GEMINI22 loads the annotated VCF into a
relational database (GEMINI can also load files annotated with Variant Effect Predictor (VEP)25,
although VEP is not available as part of our pipeline). Step 12 uses a custom Python script to
extract CH variant data from the database. Our provided script identifies CH variants and filters
the data based on user-set thresholds for global minor allele frequency (MAF) and Combined
Annotation Dependent Depletion (CADD) scores26 . Variants with a MAF less than or equal to
the user-set threshold, CADD score greater than or equal to the user-set threshold, exonic
classification , and “HIGH” or “MED” putative impact severity are included in the final output.
We consider the variants in the final output as candidates for further evaluation. For step 12, we
provide two additional scripts that identify homozygous alternate variants and de novo variants
using the same user-set thresholds as those described above.

Finally, in step 13, we add Gene Damage Index (GDI) scores27 and gene-length information to
the output files. GDI scores quantify accumulated mutational damage in healthy populations as a
way to predict whether genes are likely to have disease-causing variants. Genes of longer length
(e.g. TTN, MUC5B) tend to have more total damage but typically less disease-causing damage
than shorter genes.

Operation
Because CompoundHetVIP executes all scripts within a Docker container, it can be executed on
all major operating systems that are commonly used for scientific computing. Depending on
input file sizes, the hardware needed to execute CompoundHetVIP will vary from user to user.
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Certain tasks, such as phasing (step 6), can be memory intensive. A minimum of 40 GB memory
is recommended. When creating a relational database with GEMINI (step 11), there is no
minimum processing core recommendation, but multiprocessing can significantly speed up the
time it takes to load the database. Users can specify how many processing cores GEMINI can use
when executing step 11.

Results
We applied CompoundHetVIP to high-confidence, VCF data that were generated with wholegenome sequencing data from an Ashkenazim trio available through the Genome in a Bottle
Consortium28 . During step 6, we used SHAPEIT2 to phase the data. In the child of this trio, we
identified a CH variant in two genes (FLNB and TTN) using a MAF threshold of 0.01 and a
CADD score threshold of 15. Genes with a GDI score less than or equal to 13.84 are classified as
being more likely to have disease-causing damage from variants27 . FLNB (6.2) was lower than
this threshold but TTN (42.9) was not. FLNB has an important role in cytoskeleton development
and variations in this gene have been associated with many skeletal disorders 29, 30.

In addition, we identified two homozygous alternate variants: one in TBC1D2 and the other in
TOX2, using the same MAF and CADD thresholds that we used for CH variant identification.
TBC1D2 and TOX2 had GDI scores of 9.7 and 4.4, respectively. TBC1D2 codes for a GTPaseactivating protein and is involved in E-cadherin degradation31. The role of this gene and how it
may relate to human disease is not yet fully understood. TOX2 is a transcription factor that helps
drive the development of T follicular helper (Tfh) cells32. Tfh cells are an important part of
humoral immunity.
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Using the same MAF and CADD thresholds described above, we sought to identify de novo
variants in this trio. However, none passed these thresholds.

Conclusion
CompoundHetVIP provides the necessary tools for CH variant identification using VCF or
gVCF files as initial input and is executed within a Docker container, which allows for crossplatform compatibility and reproducibility. CompoundHetVIP involves 13 steps (Fig. 2.1) that
include a breadth of tasks such as file aggregation, VCF liftover, joint-genotyping, file
conversion, phasing, variant normalization, annotating, and variant identification. Our results
highlight that potentially damaging CH and homozygous alternate variants are observed in
seemingly healthy individuals. However, we anticipate that most researchers will use
CompoundHetVIP to identify variants in individuals with a known disease.

Data Availability
Source Data
VCF data used to generate the results were from an Ashkenazim trio, freely-available through
the Genome in a Bottle Consortium at ftp://ftptrace.ncbi.nlm.nih.gov/giab/ftp/release/AshkenazimTrio/ 27 :
- Child: ftp://ftptrace.ncbi.nlm.nih.gov/giab/ftp/release/AshkenazimTrio/HG002_NA24385_son/latest/G
RCh38/supplementaryFiles/HG002_GRCh38_CHROM1-22_v4.1_highconf.vcf.gz
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- Mother: ftp://ftptrace.ncbi.nlm.nih.gov/giab/ftp/release/AshkenazimTrio/HG004_NA24143_mother/latest
/GRCh38/HG004_GRCh38_GIAB_highconf_CG-Illfb-IllsentieonHC-Ion10XsentieonHC_CHROM1-22_v.3.3.2_highconf.vcf.gz
- Father: ftp://ftptrace.ncbi.nlm.nih.gov/giab/ftp/release/AshkenazimTrio/HG003_NA24149_father/latest/
GRCh38/HG003_GRCh38_GIAB_highconf_CG-Illfb-IllsentieonHC-Ion10XsentieonHC_CHROM1-22_v.3.3.2_highconf.vcf.gz

Extended Data
Zenodo: dmiller903/CompoundHetVIP: CompoundHetVIP - v1.1.
https://doi.org/10.5281/zenodo.447768312 .
This project contains the following extended data:
•

- CompoundHetVIP_example.pdf (detailed step-by-step example)

•

Software Availability
Software available from: https://hub.docker.com/r/dmill903/compound-het-vip
Source code available from: https://github.com/dmiller903/CompoundHetVIP
Archived source code at time of publication: https://doi.org/10.5281/zenodo.447768312 .
License: MIT
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Figure 2.1. Flow diagram of CompoundHetVIP functionality.
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Abstract
Compound heterozygous (CH) variants occur when two recessive alleles are inherited and the
variants are located at different loci within the same gene in a given individual. CH variants are
important contributors to many different types of recessively inherited diseases. However, many
studies overlook CH variants because identification of this type of variant requires knowing the
parent of origin for each nucleotide. Using computational methods, haplotypes can be inferred
using a process called "phasing", which estimates the chromosomal origin of most nucleotides.
In this paper, we used germline, phased, whole-genome sequencing data to identify CH variants
across seven pediatric diseases (adolescent idiopathic scoliosis: n = 16, congenital heart defects:
n = 709, disorders of sex development: n = 79, ewing sarcoma: n = 287, neuroblastoma: n = 259,
orofacial cleft: n = 107, and syndromic cranial dysinnervation: n = 172), available as parent-child
trios in the Gabriella Miller Kids First Data Resource Center. Relatively little is understood
about the genetic underpinnings of these diseases. We classified CH variants as “potentially
damaging” based on minor allele frequencies (MAF), Combined Annotation Dependent
Depletion scores, variant impact on transcription or translation, and gene-level frequencies in the
disease group compared to a healthy population. For comparison, we also identified homozygous
alternate (HA) variants, which affect both gene copies at a single locus; HA variants represent an
alternative mechanism of recessive disease development and do not require phasing. Across all
diseases, 2.6% of the samples had a potentially damaging CH variant and 16.2% had a
potentially damaging HA variant. Of these samples with potentially damaging variants, the
average number of genes per sample was 1 with a CH variant and 1.25 with a HA variant. Across
all samples, 5.1 genes per disease had a CH variant, while 35.6 genes per disease had a HA
variant; on average, only 4.3% of these variants affected common genes. Therefore, when
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seeking to identify potentially damaging variants of a putatively recessive disease, CH variants
should be considered as potential contributors to disease development. If CH variants are
excluded from analysis, important candidate genes may be overlooked.
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Introduction
Each year in the United States, ~3.0% of babies are born with a structural defect, and ~11,050
children under the age of 15 are diagnosed with pediatric cancer (American Cancer Society;
Lupo et al., 2019). Researchers are working to understand the genetic causes of these diseases,
now often via whole-genome sequencing (Zhang et al., 2015; Gröbner et al., 2018; Lupo et al.,
2019). When researchers analyze DNA sequencing data, the parent of origin for each nucleotide
is often unknown (Choi et al., 2018). While this is not an issue when looking at heterozygous
variants in dominantly inherited diseases or when identifying homozygous alternate (HA)
variants in recessively inherited diseases, it is problematic when looking at more complex
inheritance patterns, such as compound heterozygous (CH) variants (Sanjak et al., 2017). Under
the assumptions of recessive disease inheritance, in the majority of cases, a single heterozygous
variant in a gene does not result in decreased fitness of an organism (Morrill and Amon, 2019).
However, CH variants—which consist of alternate alleles positioned at different loci within a
gene on opposite homologous chromosomes—may result in no functional copies of the
associated proteins and a decrease in overall fitness. CH variants have been observed in many
pediatric diseases. For example, pathogenic CH variants in the ASXL3 gene can lead to a
disruption in ASXL3 protein expression, potentially contributing to the development of
congenital heart disease (Fu et al., 2020). Additionally, potentially damaging CH variants have
been identified in many cancer predisposition genes, across various pediatric cancer types
(Miller and Piccolo, 2020a). Although the importance of assessing CH variants in pediatric
diseases has been established, researchers may ignore these types of variants in genome-wide
studies due to additional steps required to identify and interpret them; one of these steps is
haplotype estimation via computational phasing. It has been shown that using a population-
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based, haplotype reference panel and/or trio-based samples can improve phasing as much as 10fold (Choi et al., 2018); however, this process is computationally expensive, and current phasing
algorithms require specific file formats or that reads be aligned to a specific reference genome
and be free of multi-allelic positions. These requirements may deter some researchers from
performing phasing—and thus identifying CH variants.

Prior studies involving CH variant identification have focused primarily on individual diseases,
one or a few samples, or specific genes (Miller and Piccolo, 2020a). Furthermore, little is known
about how to filter and classify CH variants in genome-wide studies. Common practice in
genetic studies is to filter variants based on population-level MAF; however, it is unclear how
this applies to CH variants because it would be infeasible to compile a database that estimates the
frequency of all possible combinations of in trans alleles in a control population. Many
combinations are extremely rare, and others are private to a single individual. Furthermore, the
number of possible combinations will differ by gene—many more combinations can occur in
longer genes than shorter ones.

In this study, we surveyed germline CH variants in a total of 1,629 affected samples across 7
pediatric diseases: adolescent idiopathic scoliosis, congenital heart defects, disorders of sex
development, ewing sarcoma, neuroblastoma, orofacial cleft, and syndromic cranial
dysinnervation. Little is understood about the genetic underpinnings of these diseases (Beaty et
al., 2016; Eggers et al., 2016; Grauers et al., 2016; Brohl et al., 2017; Singh et al., 2017; Tolbert
et al., 2017; Pierpont et al., 2018). We used whole-genome sequencing data from the Gabriella
Miller Kids First initiative, which has a mission of generating high-quality sequencing data for
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large cohorts of pediatric-disease patients and making those data available for broad use (Heath
et al., 2019). For most probands, sequencing data were available for the affected child and both
of her/his parents. Thus, we were able to estimate haplotypes using the best-available
computational-phasing approach (Delaneau et al., 2013; Choi et al., 2018). We used
computational tools to estimate pathogenicity of individual alleles within a given gene and then
identified genes with multiple, potentially pathogenic alleles on homologous chromosomes. To
better understand the frequency of CH variants in the general population, we estimated genelevel frequencies of CH variants in healthy controls and used these as a comparison group
against our probands. Finally, we compared the observed frequencies of CH variants in each
disease against the frequencies of HA variants. The resulting observations yielded novel insights
about how often CH variants occur in diverse pediatric diseases, how one disease compares to
another, and genes that may play a role in recessive inheritance of these pediatric diseases. This
study is the first to report multi-cohort, genome-wide evaluations of CH variants in pediatric
diseases.

Methods
Disease Cohorts
We analyzed trio data stored in the Gabriella Miller Kids First Data Resource Center (Heath et
al., 2019). These data were generated via Illumina-based, whole-genome sequencing (WGS) of
non-disease cells (Gabriella Miller Kids First Pediatric Research Program) from each proband
and their parents. The diseases we studied are adolescent idiopathic scoliosis (16 trios),
congenital heart defects (709 trios), disorders of sex development (79 trios), Ewing's sarcoma
(287 trios), neuroblastoma (259 trios), orofacial cleft (107 trios), and syndromic cranial
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dysinnervation (172 trios). Specific diagnoses for each disease are in Supplementary: T1. Trios
were selected based on whether or not they were labeled as a trio in the database and DNA
variant data were available for all three members of the trio. In addition, we filtered patients
based on research use consent status. For all diseases except syndromic cranial dysinnervation,
we used trios that had been consented for general research use or health/medical/biomedical use.
For syndromic cranial dysinnervation, we used trios that were consented for disease-specific use
(in accordance with data-use restrictions).

Variant Identification for Disease Cohorts
In the Gabriella Miller Kids First Data Resource Center, germline variant data are provided as
gVCF files (Poplin et al., 2017). Using these files as input, we identified CH and HA variants in
a series of steps including file aggregation, liftover, phasing, annotation, and filtering (described
below and in Fig. 3.1). We completed these steps using scripts adapted from the
CompoundHetVIP pipeline (Miller and Piccolo, 2020b). These and other scripts are available in
an open-source repository at https://github.com/dmiller903/CompoundHetVIP-GMKF. This
repository contains Python scripts (https://python.org) with custom code for parsing metadata
and handling the gVCF files in a way that is specific to the Gabriella Miller Kids First Data
Resource Center. All of these scripts are stored within a Docker image, which is available at:
https://hub.docker.com/r/dmill903/compound-het-vip-gmkf. A detailed example of how data
from each disease was processed can be viewed at:
https://github.com/dmiller903/CompoundHetVIP-GMKF/blob/master/usage_example.pdf.
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For each disease, gVCF, clinical, and manifest files were downloaded from the Gabriella Miller
Kids First Data Resource Center. These files were downloaded in September 2019 (adolescent
idiopathic scoliosis), January 2020 (disorders sex development), February 2020 (Ewing’s
sarcoma), March 2020 (congenital heart defects, orofacial cleft, syndromic cranial
dysinnervation), and April 2020 (orofacial cleft). The clinical and manifest files contain
information about file names, sample ID’s, family relationships, disease status, etc. The
information from the clinical and manifest files were combined using the “kids_first_meta.py”
script. The resulting combined file was used as input to many of the subsequent scripts to keep
track of file names, family relationships, probands, etc. Unlike VCF files (Danecek et al., 2011),
gVCF files contain information for variant sites as well as non-variant positions (Poplin et al.,
2017). These files are large and would take much longer to process if non-variant positions were
included throughout the whole pipeline. Therefore, using the "keep_variant_sites.py" script, we
removed all non-variant positions for each proband (Fig. 3.1). Using the variant positions of the
proband as a reference, the script then retained the same positions in each parent’s gVCF file
(regardless of whether the position was variant or non-variant).

The "combine_trios.py" script was used for each trio to combine data from all family members
into a single file; we used Genome Analysis Toolkit (GATK) (version 4.0.5.1) for this step
(Poplin et al., 2017) (Fig. 3.1). In addition, the script created a “.fam” file to be used later in
processing. As part of its data-processing pipeline, the KFDRC had aligned reads to build
GRCh38 of the human reference genome (Schneider et al., 2016). Alignment to this build was an
issue because subsequent tools in our pipeline required the files to be aligned to GRCh37.
Therefore, our “liftover.py” script joint-genotyped the combined trio files using GATK and
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converted the coordinates to GRCh37 using Picard's (Picard Tools) Liftover tool. During
liftover, some sites with unknown positions in the GRCh37 build were included in the VCF file;
we created a “remove_unplaced_multiallelic.py” script to remove these positions. In addition,
the script removed multiallelic or duplicate positions because programs such as PLINK2 (Purcell
and Chang; Chang et al., 2015) (used next) and SHAPEIT2 (Delaneau et al., 2013) (used later)
cannot handle these types of sites. For each trio, sites containing missing genotype information
(i.e. "./.") for both parents were removed to improve phasing accuracy.

SHAPEIT2 requires chromosomes to be phased separately. PLINK files are also needed by
SHAPEIT2 during phasing. Our "separate_chr_generate_plink.py" script separated the data for
each trio file into chromosome files (autosomes only) and executed PLINK to generate the files
needed for phasing (.bed, .bim, .fam). Next, we used "phase_with_shapeit.py" to phase each
chromosome. The parameters for phasing were set so that SHAPEIT2 used family relationship
genotype information and also used the 1000 Genomes Project (1000GP) phase 3 haplotype
reference panel. Default parameters were used. The files used for phasing can be found at
https://mathgen.stats.ox.ac.uk/impute/1000GP_Phase3.html and through the 1000GP online
database (1000 Genomes Project Consortium et al., 2015).

In some cases, SHAPEIT2 switches the REF and ALT alleles during phasing. Our
"alt_ref_revert.py" script ensured that the REF/ALT alleles of the phased VCF files were
congruent with the REF/ALT order of the reference genome. In addition, it removed sites with
Mendelian errors. To make subsequent analysis of the phased files easier,
"concat_merge_phased_vcf.py" executed bcftools (Li, 2011) (version 1.9) to concatenate all
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phased chromosomes for each trio into a single trio file. Finally, using bcftools, each
concatenated trio file was merged into a single VCF file containing all trios for a particular
disease, and a .fam file was created for this merged file.

As a preprocessing step, GEMINI (Paila et al., 2013) recommends left trimming and normalizing
VCF files using vt tools (Tan et al., 2015). Our “vt_split_trim_left_align.py" script used vt tools
(version 2015.11.10) to trim and normalize the phased VCF file. Next, "annotate.py" executed
snpEff (Cingolani et al., 2012) to annotate the variants with information about whether or not a
variant is in a gene, the type of variant, the predicted effect the variant may have on protein
coding (i.e. variant impact severity, and whether or not the variant causes loss of protein
function), etc.

GEMINI (version 0.30.2) allowed us to provide additional annotations and then filter and
summarize the annotated genetic variants. The "gemini_load.py" script loaded the VCF file into
a GEMINI database, which provided information such as Combined Annotation Dependent
Depletion (CADD) scores (Rentzsch et al., 2019) and MAF from the 1000GP (1000 Genomes
Project Consortium et al., 2015) or gnomAD (Karczewski et al., 2020) (version 2.1). The
“identify_CH_variants.py” script first exports the GEMINI database to a .tsv file and then uses
that file to identify CH variants. CH variants were identified based on five criteria: 1) whether
snpEff classified each of the alleles contributing to the CH variant as "HIGH" impact, 2) whether
each allele had a CADD score >= 15, 3) neither parent was HA at either allele as a HA allele
would unlikely be damaging given that it is present in a healthy parent, 4) neither parent had the
exact same alleles making up a CH variant as found in the child, and 5) at least one allele of the
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CH variant had a MAF <= 5% (gnomAD MAF used as priority over 1000GP). We allowed one
of the alleles to have a MAF > 5% to include scenarios where a single, damaging, common allele
does not have a phenotypic effect when found to be heterozygously inherited, but may have a
phenotypic effect when paired with a different, damaging, rare allele found on the opposite
chromosome at a different position within the same gene. The genes in the final output are
referred to as having “potentially damaging” variants.

To identify HA variants, the “identify_HA_variants.py” script was used. This script used the
same GEMINI database and selected variants that were of "HIGH" impact, had a MAF <= 5%,
and a CADD score >= 15. HA variants for which either parent had a HA variant at the same
position as the child were excluded from the final output file.

Identification of CH and HA Variants in 1000 Genomes Samples
Data from the 1000GP (1000 Genomes Project Consortium et al., 2015) were used as a baseline
to better understand the frequency of potentially damaging CH and HA variants in the general
population. Phased VCF data for the 1000GP were obtained from
ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/release/20130502/. This repository contains
genotypes/haplotypes for 2,504 unrelated individuals. Because these files had previously been
phased using a combination of Beagle (Browning and Browning, 2007) and SHAPEIT2, many of
the steps required for the GMKF data were unnecessary. We processed chromosome-level VCF
files (autosomes only) starting with the "concat_merge_phased_vcf.py" script and and
progressing until the "add_GDI_and_gene_lengths.py" script in the CompoundHetVIP pipeline
(Miller and Piccolo, 2020b), a generalized version of the pipeline that was used to identify
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variants in the GMKF data. Because the 1000GP data does not contain trios or other family
relationships, the “identify_CH_variants.py” script was not able to exclude variants based on
observations in parents. However, we used the same CADD, MAF, and impact filtering criteria
for the 1000 Genomes data as what we used for the GMKF variants.

Filtering CH Variants Using 1000 Genomes Data as Reference
Using RStudio (RStudio Team (2020)) (version 1.2.5042), R(R Core Team (2020)) (version
3.6.3) and the tidyverse package (Wickham et al., 2019) (version 1.3.0), we further filtered the
genes using potentially damaging CH variants from 1000GP as a reference. We identified genes
in which a CH variant was present in more than 1% of the 1000 Genome samples and excluded
these genes from the GMKF analysis. This same logic was used to filter the HA variants.

Known Tumor Suppressor and Developmental Genes
Because inherited DNA variations in germline tissue can contribute to the inactivation of tumor
suppressor genes and result in subsequent cancer development (Wang et al., 2018), we used R to
identify which of the genes with potentially damaging CH and HA variants were in known tumor
suppressor genes. In addition, given that both structural birth defects and pediatric cancers tend
to occur at an early age, we identified which of the potentially damaged genes were in known
developmental biology genes. During the identification process, a list of known tumor suppressor
genes from Cancer Gene Census and a list of known developmental genes from Reactome
(Reactome Developmental Biology pathway: R-HSA-1266738) were used (Sondka et al., 2018;
Jassal et al., 2020). For these genes and all genes identified with potentially damaging CH
variants, we used DisGeNET to determine whether any gene-disease associations had been
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identified in previous studies (Piñero et al., 2020). DisGeNET uses many different databases
(e.g. UniProt, ClinVar, etc.) to establish gene-disease associations. One metric DisGeNET
provides is a gene-disease association (GDA) score which ranges from 0 to 1. The more sources
and publications that support a gene-disease association, the higher the value. We considered
GDA values greater than or equal to 0.5 as strong evidence for a gene-disease association. In
addition to GDA scores, we used DisGeNET to produce variant-disease association (VDA)
scores for each potentially damaging variant contributing to a CH variant. VDA scores follow
the same scale as GDA scores.

Pathway Analysis of Genes Containing Potentially Pathogenic CH Variants
Pathway enrichment analysis can help determine whether specific biological pathways are
significantly enriched based on a list of candidate genes (Reimand et al., 2019). We used the R
and the ReactomePA (Yu and He, 2016) package (version 1.30.0), to perform a pathway
enrichment analysis for each disease. Default parameters were used. For each disease, the genes
with CH variants that were retained after 1000GP data filtering were used as input. Pathways that
had an adjusted p-value (adjusted using the Benjamini-Hochberg False Discovery Rate method
(Benjamini and Hochberg, 1995)) less than or equal to 0.05 and a q-value less than or equal to
0.2 were retained.

Results
In this study, we focus on scenarios in which at least two alternate alleles occurred on different
chromosomes in the same gene and/or locus; thus, we assume the diseases follow an autosomalrecessive inheritance pattern in some cases and that these traits are subject to Mendelian
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inheritance. Autosomal-recessive and Mendelian inheritance have been associated with some
pediatric cancer types and structural birth defects (Webber et al., 2015; Zhang et al., 2015; Miller
and Piccolo, 2020a). For recessively inherited diseases, CH or HA variants may play a role if
both alleles lead to loss of protein function. Therefore, we also identified HA variants, in which
two non-reference alleles occurred at the same locus within a gene. We included these variants in
the analysis as a way to show how the number of samples and genes with potentially damaging
HA variants compares to the number of samples and genes with potentially damaging CH
variants.

Across all analyzed pediatric diseases, the median number of unphased variants per sample was
5,509,545 prior to any data processing and variant-type classifications (Fig. 3.2). After jointgenotyping, liftover, removing unplaced and multiallelic sites, phasing, and removing sites with
Mendelian errors, the median number of unphased variants per sample was 3,894,315 (Fig. 3.2).
Therefore, on average, 70.7% of the original variants were available for CH and HA
identification after these preprocessing steps. Joint-genotyping (which includes quality filtering)
and phasing led to the greatest reductions in the number of unphased variants: 613,225 and
602,443 variants removed on average, respectively (Fig. 3.2). Of the variants available for
phasing, ~86.7% were successfully phased on average. Unphased sites included those that were
incompatible with the reference panel (e.g. SNP missing in reference haplotype panel),
monomorphic or singleton SNPs (these sites are uninformative for phasing), and those with
Mendelian inheritance errors (Delaneau et al., 2013).
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Across all disease types, the initial query for CH variants resulted in 146 probands and 41 unique
genes with potentially damaging CH variants that met our minimum CADD, MAF, and geneimpact thresholds during variant identification (see Methods). Across all diseases, based on our
initial query, an average of 9.5% of the samples had at least one CH variant and there were an
average of 10.9 genes per disease with potentially damaging CH variants. To further filter these
potentially damaging variants, we used 1000GP data as a baseline of what to expect, in terms of
CH variation, in a seemingly healthy population. Potentially damaging CH variants were
identified in 151 genes and 883 samples. Of the samples with a potentially damaging CH variant,
26 of the genes were present in more than 1% of the samples (Fig. 3.3). For each disease
population, we retained genes in which a CH variant occurred in less than 1% of the 883 1000GP
samples. After this filtering step, the number of samples and genes with potentially damaging
CH variants was reduced (Table 3.1); across all diseases, the average percentage of samples with
potentially damaging CH variants decreased to 3.3% and the average number of genes per
disease with potentially damaging CH variants was 5.1 (25 total unique genes, 17 of which were
not identified as having HA variants). We observed similar results for HA variants before and
after 1000GP filtering (Table 3.2). For example, across all diseases, the average number of
samples with potentially damaging HA variants was 22.2% per disease and there were an
average of 45 genes per disease with potentially damaging HA variants. After 1000GP filtering,
the average percentage of samples with potentially damaging HA variants was 17.2% per
disease, and the average number of genes with potentially damaging HA variants was 35.6 per
disease.
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CH variants and HA variants sometimes affect common genes, generally they occur in different
genes. When researchers do not consider CH variants in genotype-phenotype studies, they may
overlook important candidate genes. In turn, overlooking candidate genes may cause the
investigator to overlook some samples by assuming that they have no potentially pathogenic
variants when, in fact, they do. Although not our focus, this is an important factor to consider
when a clinician is trying to understand what genes have contributed to a patient's disease. Using
the genes retained after filtering with 1000GP data, potentially damaging CH variants are
observed in samples and genes that HA variants are not identified in. For example, all diseases
showed a percent increase in the number of samples with potentially damaging CH variants that
did not have potentially damaging HA variants (Table 3.3). In addition, all diseases experienced
a percent increase in the number of genes with potentially damaging CH variants that did not
have potentially damaging HA variants (Table 3.4).

Given that non-functional tumor suppressor genes can lead to tumor development and given that
pediatric cancers and structural birth defects occur early in a child’s life, we sought to determine
whether any of the potentially damaged genes (after 1000GP filtering) occurred in tumor
suppressor or developmental biology genes (see Methods). Congenital heart defects was the only
disease where a CH variant was identified in a developmental biology gene (KRTAP4-7: n = 1)
(Fig. 3.4 & 3.5). However, KRTAP4-7 and the variants contributing to the CH variant identified
in this gene were not associated with congenital heart defects or any of the other diseases in this
study based on a GDA or VDA score greater than or equal to 0.5 (Piñero et al., 2020). All
diseases except adolescent idiopathic scoliosis and orofacial cleft had at least one sample with a
HA variant in a gene known to be involved in developmental biology (Fig. 3.4). No genes

69

associated with tumor suppression were identified for either disease. Variants in the
developmental biology genes ACTG1, CCND3, COL9A2, KRTAP4-7, and KRTAP4-8 were seen
in more than one disease. However, using DisGeNET, we did not identify any previous genedisease associations between the developmental biology genes and the disease(s) they were
identified in. To expand the list of candidate genes for gene-disease associations, we also
analyzed all genes that contained CH variants after 1000GP filtering (Fig. 3.5). These genes and
the CH variants identified in these genes also resulted in no GDA or VDA scores greater than or
equal to 0.5 for the diseases that they were identified in. Supplementary: T2 provides a complete
list of heterozygous variants that were identified as part of a CH variant, the genes and disease(s)
they were identified in, and the number of samples with each heterozygous variant.
Supplementary: T3 provides a complete list of HA variants, the genes and disease(s) they were
identified in, and the number of samples with each HA variant.

For each disease, we performed a pathway analysis to determine if any disease pathways were
enriched with genes containing potentially damaging CH variants. Using the genes retained after
1000GP filtering of the CH variant gene data, we identified three diseases as having enriched
pathways based on an adjusted p-value less than or equal to 0.05 and a q-value less than or equal
to 0.2 (Table 3.5): Ewing sarcoma, neuroblastoma, and orofacial cleft. Each of the enriched
pathways, across all diseases, had a single gene identified as being part of the pathway. All three
diseases had two pathways in common: the inactivation, recovery and regulation of the
phototransduction cascade, and the phototransduction cascade. These two pathways involve the
GUCA1C gene. However, no diseases were found to have a strong association with GUCA1C
based on a GDA search through DisGeNET. Other genes identified as being part of an enriched
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pathway included FUT2, MMP10, and IFIH1. These genes are not found in the Cancer Gene
Census, nor are they part of a developmental biology pathway. Supplementary: T4 provides all
pathways identified for each disease, regardless of adjusted p and q values.

Discussion
The importance of studying CH variants in pediatric diseases has been established, but to date,
the number and scope of studies that have focused on CH variants are limited. For example, most
studies on CH variants in pediatric cancers have focused on a single disease type, one or a few
different gene targets, and have not accounted for background rates of CH variation in diverse,
healthy populations (Miller and Piccolo, 2020a). A systematic review showed that since the
advent of next-generation sequencing (NGS) approximately 20 years ago, only 10 studies have
used NGS to identify CH variants in pediatric cancers (Miller and Piccolo, 2020a). Of these 10
studies, seven used trios and patterns of Mendelian inheritance to infer CH variants (Valentine et
al., 2014; Spinella et al., 2015; Diets et al., 2018; Diness et al., 2018; Zhang et al., 2018;
Maciaszek et al., 2019; Schieffer et al., 2019), two used computational phasing without the use
of trio data (Gröbner et al., 2018; Waszak et al., 2018), and one used patient RNA-seq data to
confirm the presence of a single CH variant (Zhang et al., 2015). In total, these 10 prior studies
examined 1,279 samples across nine different cancer types, and identified CH variants in 23
unique genes. While no comprehensive review has been published on the role of CH variation in
structural birth defects to date, a search on Google Scholar for ‘"structural birth defect" AND
"compound heterozygous" AND "next generation"’, limited to the last 20 years, uncovered four
studies that used trio data and Mendelian inheritance to infer CH variants (Li et al., 2015, 2020;
Takeda et al., 2017; Aarabi et al., 2018), and one study that used computational phasing without
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trio data (Jiang et al., 2018). These five studies included 1,192 samples across numerous
structural birth defect types, and identified CH variants in eight genes likely playing a role in the
formation of a defect. The computational pipelines used in these studies were inconsistent with
each other, and none took background rates of CH variation in healthy populations into
consideration. In this study, we analyzed two pediatric cancer types and five structural birth
defect diseases for CH variants across 1,629 affected individuals using a consistent,
reproducible, computational pipeline. WGS data for these individuals were phased using trio data
and a haplotype reference panel. After accounting for background rates of CH variation in the
1000GP control population, we identified 25 unique genes with at least one potentially damaging
CH variant.

During the variant-identification process for both CH and HA variants, we focused on variants in
which both alleles were classified as having "HIGH" impact severity and thus were among the
most likely to be pathogenic. Across all diseases, we identified high-impact variants that
included splice-acceptor, splice-donor, start-loss, stop-gain, stop-loss, and structural-interaction
variants. We focused on variants of high impact to help control for false positives. However, by
excluding alleles of lower impact (which may have included missense variants, in-frame
insertions or deletions, transcription-factor binding site variants, etc.), we likely excluded some
true positives. Using a healthy population as a baseline may help reduce the number of false
positives, as well as the number of candidate genes that must be considered in genotypephenotype studies. Therefore, in addition to variant-level filtering, we performed gene-level
filtering using 1000GP data. We observed potentially damaging CH variants in 883 out of 2,504
of these seemingly healthy individuals. For each disease that we studied, we identified genes
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affected with CH variants in more than 1% of 1000GP individuals and excluded these from
consideration as candidate disease genes because it is unlikely that these genes are diseasecausing, given their prevalence in this seemingly healthy population.

Due to the stringent variant-level and gene-level filtering that we used, this study erred on the
side of specificity rather than sensitivity. However, one of our goals was to estimate a lower
bound on the number of biallelic gene variants that would be missed or mischaracterized without
genome phasing. Future efforts will be necessary to refine the ability to estimate pathogenicity of
varying combinations of “HIGH”, "MODERATE", and "LOW" impact alleles in the context of
CH variant identification. Although we expect that the genes presented in this paper as having
potentially pathogenic CH variants are among the most likely to play a role in these diseases, we
likely missed other genes that should be considered. Among the genes that our filtering process
excluded are MUC19 and multiple HLA genes (HLA-DRB5, HLA-B, and HLA-DRB1). Mucin
genes are known to be highly variant and HLA genes are among the most polymorphic genes
(Akle et al., 2015; Wu et al., 2019).

Across all diseases, our analyses revealed potentially damaging CH variants in genes involved in
developmental biology (Fig. 3.4 & 3.5), but no statistically significant gene-disease associations
were identified. That is not to say that these genes have no effect on disease development. For
example, IFIH1, for which a potentially pathogenic CH variant was identified in a single
neuroblastoma patient, has been associated with lupus erythematosus (GDA score: 0.7), AicardiGoutieres syndrome (GDA score: 0.7), and Singleton-Merten syndrome (GDA score:
0.69)(Piñero et al., 2020). Of the genes identified in this study, further investigation into their
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biological role through wet lab experiments, such as gene knockdown, could reveal novel
possible mechanisms of disease development.

Phasing is computationally expensive and requires additional analysis steps. However, our
analysis shows that it is common to observe CH variants in diverse diseases, thus providing
evidence that phasing is justified. Our CH variant identification process enabled us to identify a
considerable number of potentially disease-causing variants that would not have been identified
without phasing. For example, for the pediatric diseases that we studied, the number of samples
with potentially damaging CH variants increased by 8.5-25.0%, and the number of genes in
which these variants occurred increased by 8.3-20.0% when compared to assessing HA variants
alone (Table 3.3, Table 3.4). Without phased data, across all studies, 17 genes with potentially
damaging variants would have been overlooked and 35 samples would have been overlooked as
having potentially damaging variants.

The process that we used to identify CH variants in these cohorts has various limitations. Despite
using the best available methods and tools throughout the CH variant identification process,
many variant positions were removed during preprocessing steps (Fig. 3.2). Because of this loss,
additional high impact alleles may be unaccounted for, so our results may underestimate the
number of genes with potentially damaging CH variants for these pediatric diseases. Much of the
data loss is due to current limitations of software programs or due to data-quality issues. For
example, when converting chromosomal positions from one genome build to another, the exact
position must be known in the target genome (Lowy-Gallego et al., 2019). If the position is
unknown in the target genome, the position will be excluded in the final output. Another
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software limitation that leads to data loss occurs during phasing. Phasing relies on several
factors, such as the number of high-quality variant calls and completeness of a haplotype
reference panel (Choi et al., 2018). Phasing completeness is also not guaranteed when using
family information during phasing. For example, if both parents and the child are heterozygous
at a position, or inheritance of a variant does not follow Mendelian inheritance patterns, phase
may be undetermined due to these ambiguities. Across all diseases, on average, there were
14,130 variant positions per sample removed due to Mendelian inheritance inconsistencies (Fig.
3.2). Despite these limitations, we identified many CH variants that could be explored further.

In addition to the software limitations that are part of the phasing process, phasing can be time
consuming and computationally demanding. For example, phasing a single trio can take ~4 hours
if only one CPU core is being used. However, using 22 CPU cores simultaneously, we reduced
the duration of this process to ~21 minutes per trio. Our recently developed program,
CompoundHetVIP, can help facilitate the phasing process and assist in CH variant identification;
it uses commonly used programs such as SHAPEIT2 (for phasing) and GEMINI (to assist with
CH variant identification) (Delaneau et al., 2013; Paila et al., 2013; Miller and Piccolo, 2020b).
CompoundHetVIP requires minimal command-line experience. This is one example in which
phasing and CH variant identification is becoming more easily accessible to researchers of all
computational skill levels.

Conclusion
Although much insight has been gained from recent studies focusing on the role of germline
variants in pediatric cancer and structural birth defect diseases, many studies overlook CH
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variants because identification of these variants requires sequencing data from parents as well as
additional time and computational resources. However, embracing these limitations is worth the
additional knowledge that is gained when studying diseases that are putatively inherited in a
recessive manner. Using trio data from the GMKF, across seven pediatric diseases with unknown
etiologies, we showed that the number of samples and genes with potentially damaging variants
increases when compared to the number of samples and genes with HA variants, alone. We used
1000GP data as a baseline of what to expect in terms of CH variation across a genome and then
used this information as a filter to reduce the number of candidate genes with potentially
damaging CH variants in each disease dataset. Across all seven diseases, we observed 17 genes
with potentially damaging CH variants that would have been overlooked if CH variants were not
considered. In addition to research applications, the identification of CH variants may be
beneficial to clinicians when trying to understand what genes may be contributing to a patient's
disease.

Acknowledgements
The results analyzed and published here are based in whole or in part upon data generated by
Gabriella Miller Kids First Pediatric Research Program projects phs001436, phs001138,
phs001168, phs001228, phs001247, phs001410, phs001178, and were accessed from the Kids
First Data Resource Portal (https://kidsfirstdrc.org and/or dbGaP (www.ncbi.nlm.nih.gov/gap).

76

References
1000 Genomes Project Consortium, Auton, A., Brooks, L. D., Durbin, R. M., Garrison, E. P.,
Kang, H. M., et al. (2015). A global reference for human genetic variation. Nature 526, 68–
74.
Aarabi, M., Sniezek, O., Jiang, H., Saller, D. N., Bellissimo, D., Yatsenko, S. A., et al. (2018).
Importance of complete phenotyping in prenatal whole exome sequencing. Hum. Genet.
137, 175–181.
Akle, S., Chun, S., Jordan, D. M., and Cassa, C. A. (2015). Mitigating false-positive associations
in rare disease gene discovery. Hum. Mutat. 36, 998–1003.
American Cancer Society Cancer Facts & Figures 2020. American Cancer Society. Available at:
https://www.cancer.org/cancer/cancer-in-children/key-statistics.html [Accessed October 19,
2020].
Beaty, T. H., Marazita, M. L., and Leslie, E. J. (2016). Genetic factors influencing risk to
orofacial clefts: today’s challenges and tomorrow's opportunities. F1000Res. 5, 2800.
Benjamini, Y., and Hochberg, Y. (1995). Controlling the false discovery rate: a practical and
powerful approach to multiple testing. J. R. Stat. Soc. Available at:
https://rss.onlinelibrary.wiley.com/doi/abs/10.1111/j.2517-6161.1995.tb02031.x.
Brohl, A. S., Patidar, R., Turner, C. E., Wen, X., Song, Y. K., Wei, J. S., et al. (2017). Frequent
inactivating germline mutations in DNA repair genes in patients with Ewing sarcoma.
Genet. Med. 19, 955–958.
Browning, S. R., and Browning, B. L. (2007). Rapid and accurate haplotype phasing and
missing-data inference for whole-genome association studies by use of localized haplotype
clustering. Am. J. Hum. Genet. 81, 1084–1097.

77

Chang, C. C., Chow, C. C., Tellier, L. C., Vattikuti, S., Purcell, S. M., and Lee, J. J. (2015).
Second-generation PLINK: rising to the challenge of larger and richer datasets. Gigascience
4, 7.
Choi, Y., Chan, A. P., Kirkness, E., Telenti, A., and Schork, N. J. (2018). Comparison of phasing
strategies for whole human genomes. PLoS Genet. 14, e1007308.
Cingolani, P., Platts, A., Wang, L. L., Coon, M., Nguyen, T., Wang, L., et al. (2012). A program
for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs
in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3. Fly 6, 80–92.
Danecek, P., Auton, A., Abecasis, G., Albers, C. A., Banks, E., DePristo, M. A., et al. (2011).
The variant call format and VCFtools. Bioinformatics 27, 2156–2158.
Delaneau, O., Howie, B., Cox, A. J., Zagury, J.-F., and Marchini, J. (2013). Haplotype
estimation using sequencing reads. Am. J. Hum. Genet. 93, 687–696.
Diets, I. J., Waanders, E., Ligtenberg, M. J., van Bladel, D. A. G., Kamping, E. J.,
Hoogerbrugge, P. M., et al. (2018). High Yield of Pathogenic Germline Mutations Causative
or Likely Causative of the Cancer Phenotype in Selected Children with Cancer. Clin.
Cancer Res. 24, 1594–1603.
Diness, B. R., Risom, L., Frandsen, T. L., Hansen, B., Andersen, M. K., Schmiegelow, K., et al.
(2018). Putative new childhood leukemia cancer predisposition syndrome caused by
germline bi-allelic missense mutations in DDX41. Genes Chromosomes Cancer 57, 670–
674.
Eggers, S., Sadedin, S., van den Bergen, J. A., Robevska, G., Ohnesorg, T., Hewitt, J., et al.
(2016). Disorders of sex development: insights from targeted gene sequencing of a large
international patient cohort. Genome Biol. 17, 243.

78

Fu, F., Li, R., Lei, T.-Y., Wang, D., Yang, X., Han, J., et al. (2020). Compound heterozygous
mutation of the ASXL3 gene causes autosomal recessive congenital heart disease. Hum.
Genet. doi:10.1007/s00439-020-02200-z.
Gabriella Miller Kids First Pediatric Research Program National Institutes of Health Office of
Strategic Coordination - The Common Fund. Available at:
https://commonfund.nih.gov/kidsfirst [Accessed March 26, 2019].
Grauers, A., Einarsdottir, E., and Gerdhem, P. (2016). Genetics and pathogenesis of idiopathic
scoliosis. Scoliosis Spinal Disord 11, 45.
Gröbner, S. N., Worst, B. C., Weischenfeldt, J., Buchhalter, I., Kleinheinz, K., Rudneva, V. A.,
et al. (2018). The landscape of genomic alterations across childhood cancers. Nature 555,
321–327.
Heath, A. P., Taylor, D. M., Zhu, Y., Raman, P., Lilly, J., Storm, P., et al. (2019). Abstract 2464:
Gabriella Miller Kids First Data Resource Center: Harmonizing clinical and genomic data to
support childhood cancer and structural birth defect research. Cancer Res. 79, 2464–2464.
Jassal, B., Matthews, L., Viteri, G., Gong, C., Lorente, P., Fabregat, A., et al. (2020). The
reactome pathway knowledgebase. Nucleic Acids Res. 48, D498–D503.
Jiang, T., Huang, M., Jiang, T., Gu, Y., Wang, Y., Wu, Y., et al. (2018). Genome-wide
compound heterozygosity analysis highlighted 4 novel susceptibility loci for congenital
heart disease in Chinese population. Clin. Genet. 94, 296–302.
Karczewski, K. J., Francioli, L. C., Tiao, G., Cummings, B. B., Alföldi, J., Wang, Q., et al.
(2020). The mutational constraint spectrum quantified from variation in 141,456 humans.
Nature 581, 434–443.
Li, H. (2011). A statistical framework for SNP calling, mutation discovery, association mapping

79

and population genetical parameter estimation from sequencing data. Bioinformatics 27,
2987–2993.
Li, N., Zhou, P., Tang, H., He, L., Fang, X., Zhao, J., et al. (2020). In-depth analysis reveals
complex molecular etiology of idiopathic cerebral palsy. Cold Spring Harbor Laboratory,
2020.08.17.255158. doi:10.1101/2020.08.17.255158.
Li, Y., Garrod, A. S., Madan-Khetarpal, S., Sreedher, G., McGuire, M., Yagi, H., et al. (2015).
Respiratory motile cilia dysfunction in a patient with cranioectodermal dysplasia. Am. J.
Med. Genet. A 167A, 2188–2196.
Lowy-Gallego, E., Fairley, S., Zheng-Bradley, X., Ruffier, M., Clarke, L., Flicek, P., et al.
(2019). Variant calling on the GRCh38 assembly with the data from phase three of the 1000
Genomes Project. Wellcome Open Res 4, 50.
Lupo, P. J., Mitchell, L. E., and Jenkins, M. M. (2019). Genome-wide association studies of
structural birth defects: A review and commentary. Birth Defects Res 111, 1329–1342.
Maciaszek, J. L., Oak, N., Chen, W., Hamilton, K. V., McGee, R. B., Nuccio, R., et al. (2019).
Enrichment of heterozygous germline RECQL4 loss-of-function variants in pediatric
osteosarcoma. Cold Spring Harb Mol Case Stud 5, a004218.
Miller, D. B., and Piccolo, S. R. (2020a). Compound Heterozygous Variants in Pediatric
Cancers: A Systematic Review. Front. Genet. 11, 493.
Miller, D. B., and Piccolo, S. R. (2020b). CompoundHetVIP: Compound Heterozygous Variant
Identification Pipeline. F1000Res. 9, 1211.
Morrill, S. A., and Amon, A. (2019). Why haploinsufficiency persists. Proc. Natl. Acad. Sci. U.
S. A. 116, 11866–11871.
Paila, U., Chapman, B. A., Kirchner, R., and Quinlan, A. R. (2013). GEMINI: integrative

80

exploration of genetic variation and genome annotations. PLoS Comput. Biol. 9, e1003153.
Picard Tools http://broadinstitute.github.io/picard/. Available at:
http://broadinstitute.github.io/picard/ [Accessed April 17, 2020].
Pierpont, M. E., Brueckner, M., Chung, W. K., Garg, V., Lacro, R. V., McGuire, A. L., et al.
(2018). Genetic Basis for Congenital Heart Disease: Revisited: A Scientific Statement From
the American Heart Association. Circulation 138, e653–e711.
Piñero, J., Ramírez-Anguita, J. M., Saüch-Pitarch, J., Ronzano, F., Centeno, E., Sanz, F., et al.
(2020). The DisGeNET knowledge platform for disease genomics: 2019 update. Nucleic
Acids Res. 48, D845–D855.
Poplin, R., Ruano-Rubio, V., DePristo, M. A., Fennell, T. J., Carneiro, M. O., Van der Auwera,
G. A., et al. (2017). Scaling accurate genetic variant discovery to tens of thousands of
samples. bioRxiv, 201178. doi:10.1101/201178.
Purcell, S., and Chang, C. PLINK 2.0. Available at: www.cog-genomics.org/plink/2.0/.
R Core Team (2020) R: A language and environment for statistical computing. Available at:
https://www.R-project.org/.
Reimand, J., Isserlin, R., Voisin, V., Kucera, M., Tannus-Lopes, C., Rostamianfar, A., et al.
(2019). Pathway enrichment analysis and visualization of omics data using g:Profiler,
GSEA, Cytoscape and EnrichmentMap. Nat. Protoc. 14, 482–517.
Rentzsch, P., Witten, D., Cooper, G. M., Shendure, J., and Kircher, M. (2019). CADD:
predicting the deleteriousness of variants throughout the human genome. Nucleic Acids Res.
47, D886–D894.
RStudio Team (2020) RStudio: integrated development for R. RStudio, PBC, Boston, MA.
Available at: http://www.rstudio.com/.

81

Sanjak, J. S., Long, A. D., and Thornton, K. R. (2017). A Model of Compound Heterozygous,
Loss-of-Function Alleles Is Broadly Consistent with Observations from Complex-Disease
GWAS Datasets. PLoS Genet. 13, e1006573.
Schieffer, K. M., Varga, E., Miller, K. E., Agarwal, V., Koboldt, D. C., Brennan, P., et al.
(2019). Expanding the clinical history associated with syndromic Klippel-Feil: A unique
case of comorbidity with medulloblastoma. Eur. J. Med. Genet. 62, 103701.
Schneider, V. A., Graves-Lindsay, T., Howe, K., Bouk, N., Chen, H.-C., Kitts, P. A., et al.
(2016). Evaluation of GRCh38 and de novo haploid genome assemblies demonstrates the
enduring quality of the reference assembly. 072116. doi:10.1101/072116.
Singh, A., Pandey, P. K., Agrawal, A., Mittal, S. K., Rana, K. M., and Bahuguna, C. (2017).
Congenital cranial dysinnervation disorders. Int. Ophthalmol. 37, 1369–1381.
Sondka, Z., Bamford, S., Cole, C. G., Ward, S. A., Dunham, I., and Forbes, S. A. (2018). The
COSMIC Cancer Gene Census: describing genetic dysfunction across all human cancers.
Nat. Rev. Cancer 18, 696–705.
Spinella, J.-F., Healy, J., Saillour, V., Richer, C., Cassart, P., Ouimet, M., et al. (2015). Wholeexome sequencing of a rare case of familial childhood acute lymphoblastic leukemia reveals
putative predisposing mutations in Fanconi anemia genes. BMC Cancer 15, 539.
Takeda, K., Kou, I., Kawakami, N., Iida, A., Nakajima, M., Ogura, Y., et al. (2017). Compound
Heterozygosity for Null Mutations and a Common Hypomorphic Risk Haplotype in TBX6
Causes Congenital Scoliosis. Hum. Mutat. 38, 317–323.
Tan, A., Abecasis, G. R., and Kang, H. M. (2015). Unified representation of genetic variants.
Bioinformatics 31, 2202–2204.
Tolbert, V. P., Coggins, G. E., and Maris, J. M. (2017). Genetic susceptibility to neuroblastoma.

82

Curr. Opin. Genet. Dev. 42, 81–90.
Valentine, M. C., Linabery, A. M., Chasnoff, S., Hughes, A. E. O., Mallaney, C., Sanchez, N., et
al. (2014). Excess congenital non-synonymous variation in leukemia-associated genes in
MLL- infant leukemia: a Children’s Oncology Group report. Leukemia 28, 1235–1241.
Wang, L.-H., Wu, C.-F., Rajasekaran, N., and Shin, Y. K. (2018). Loss of Tumor Suppressor
Gene Function in Human Cancer: An Overview. Cell. Physiol. Biochem. 51, 2647–2693.
Waszak, S. M., Northcott, P. A., Buchhalter, I., Robinson, G. W., Sutter, C., Groebner, S., et al.
(2018). Spectrum and prevalence of genetic predisposition in medulloblastoma: a
retrospective genetic study and prospective validation in a clinical trial cohort. Lancet
Oncol. 19, 785–798.
Webber, D. M., MacLeod, S. L., Bamshad, M. J., Shaw, G. M., Finnell, R. H., Shete, S. S., et al.
(2015). Developments in our understanding of the genetic basis of birth defects. Birth
Defects Res. A Clin. Mol. Teratol. 103, 680–691.
Wickham, H., Averick, M., Bryan, J., Chang, W., François, R., Grolemund, G., et al. (2019).
Welcome to the Tidyverse. Journal of Open Source Software 4, 1686.
Wu, R., Li, H., Peng, D., Li, R., Zhang, Y., Hao, B., et al. (2019). Revisiting the potential power
of human leukocyte antigen (HLA) genes on relationship testing by massively parallel
sequencing-based HLA typing in an extended family. J. Hum. Genet. 64, 29–38.
Yu, G., and He, Q.-Y. (2016). ReactomePA: an R/Bioconductor package for reactome pathway
analysis and visualization. Mol. Biosyst. 12, 477–479.
Zhang, J., Walsh, M. F., Wu, G., Edmonson, M. N., Gruber, T. A., Easton, J., et al. (2015).
Germline Mutations in Predisposition Genes in Pediatric Cancer. N. Engl. J. Med. 373,
2336–2346.

83

Zhang, L., Jin, Y., Zheng, K., Wang, H., Yang, S., Lv, C., et al. (2018). Whole-Genome
Sequencing Identifies a Novel Variation of WAS Gene Coordinating With Heterozygous
Germline Mutation of APC to Enhance Hepatoblastoma Oncogenesis. Front. Genet. 9, 668.

84

Tables and Figures
Chapter 3 Tables
Table 3.1. The number of genes and samples with potentially damaging CH variants before
and after filtering with the 1000GP data. For each disease dataset, genes that contained CH
variants in less than or equal to 1% of the 1000GP samples were kept.

Disease

Number of
Genes with CH
variants based on
initial query

Number of
Genes with CH
variants after
filtering with
1000GP data

Number of
Samples with
CH variants
based on initial
query

Number of
Samples with
CH variants after
filtering with
1000GP data

Adolescent
Idiopathic
Scoliosis

3

1

2 (12.5%)

1 (6.3%)

Congenital Heart 29
Defects

15

63 (8.9%)

18 (2.5%)

Disorders of Sex
Development

6

2

9 (11.4%)

2 (2.5%)

Ewing Sarcoma

12

6

24 (8.4%)

7 (2.4%)

Neuroblastoma

14

5

26 (10%)

5 (1.9%)

Orofacial Cleft

4

3

7 (6.5%)

4 (3.7%)

Syndromic
Cranial
Dysinnervation

8

4

15 (8.7%)

6 (3.5%)
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Table 3.2. The number of genes and samples with potentially damaging HA variants before
and after filtering with the 1000GP data. For each disease dataset, genes that contained HA
variants in less than or equal to 1% of the 1000GP samples were kept.

Disease

Number of
Genes with
HA variants
based on
initial query

Number of Genes
with HA variants
aftering filtering
with 1000GP data

Number of
Samples
with HA
variants
based on
initial query

Number of
Samples with HA
variants after
filtering with
1000GP data

Adolescent
Idiopathic Scoliosis

7

5

4 (25%)

4 (25%)

Congenital Heart
Defects

134

102

193 (27.2%)

129 (18.2%)

Disorders of Sex
Development

33

24

20 (25.3%)

18 (22.8%)

Ewing Sarcoma

47

39

54 (18.8%)

37 (12.9%)

Neuroblastoma

43

35

53 (20.5%)

36 (13.9%)

Orofacial Cleft

19

16

19 (17.8%)

13 (12.1%)

Syndromic Cranial
Dysinnervation

32

28

36 (20.9%)

27 (15.7%)
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Table 3.3. Total number of unique samples with potentially damaging CH variants. The
number of samples with potentially damaging HA variants and the number of unique samples
(not seen with potentially damaging HA variants) with potentially damaging CH variants after
filtering with 1000GP data.

Disease

Total
Samples
in Study

Total Samples
with HA variants
after filtering
with 1000GP
data

Unique Samples Percent Increase
with CH variants in the number of
after filtering
samples
with 1000GP
data

Adolescent
Idiopathic
Scoliosis

16

4

1

25

Congenital
Heart Defects

709

129

11

8.5

Disorders of
Sex
Development

79

18

2

11.1

Ewing
Sarcoma

287

37

7

18.9

Neuroblastoma

259

36

5

13.9

Orofacial Cleft

105

13

3

23.1

Syndromic
Cranial
Dysinnervation

172

27

6

22.2
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Table 3.4. Total number of unique genes with potentially damaging CH variants. The
number of genes with potentially damaging HA variants and the number of unique genes
(potentially damaging HA variants not identified in gene) with potentially damaging CH variants
after filtering with 1000GP data.

Disease

Total number of
genes with potentially
damaging HA
variants after 1000
GP filtering

Number of unique
genes with CH
variants after
1000GP filtering

Percent increase in
the number of
potentially
damaging genes

Adolescent Idiopathic 5
Scoliosis

1

20

Congenital Heart
Defects

102

11

10.8

Disorders of Sex
Development

24

2

8.3

Ewing Sarcoma

39

5

12.8

Neuroblastoma

35

4

11.4

Orofacial Cleft

16

3

18.8

Syndromic Cranial
Dysinnervation

28

3

10.7
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Table 3.5. Pathways enriched with genes containing potentially damaging CH variants.
Genes used in Pathway Enrichment Analyses are those that were retained after filtering with
1000GP data. Ewing sarcoma, neuroblastoma, and orofacial cleft were the only diseases with
significantly enriched pathways (FDR adjusted p-value <= 0.05 and q-Value <= 0.2). The gene
that was identified in each pathway is in parentheses.

Disease

Enriched Pathway

Adjusted q-value
p-value

Ewing sarcoma

ABO blood group biosynthesis (FUT2)

0.014

0.006

Lewis blood group biosynthesis (FUT2)

0.028

0.013

Blood group systems biosynthesis (FUT2)

0.028

0.013

Inactivation, recovery and regulation of the
phototransduction cascade (GUCA1C)

0.028

0.013

The phototransduction cascade (GUCA1C)

0.028

0.013

Activation of Matrix Metalloproteinases (MMP10)

0.028

0.013

Collagen degradation (MMP10)

0.041

0.019

Inactivation, recovery and regulation of the
phototransduction cascade (GUCA1C)

0.018

0.008

The phototransduction cascade (GUCA1C)

0.018

0.008

Visual phototransduction (GUCA1C)

0.038

0.018

NF-kB activation through FADD/RIP-1 pathway
mediated by caspase-8 and -10 (IFIH1)

0.018

0.008

TRAF3-dependent IRF activation pathway (IFIH1)

0.018

0.008

TRAF6 mediated NF-kB activation (IFIH1)

0.018

0.008

TRAF6 mediated IRF7 activation (IFIH1)

0.018

0.008

Negative regulators of DDX58/IFIH1 signaling
(IFIH1)

0.018

0.008

Neuroblastoma
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Orofacial cleft

Ovarian tumor domain proteases (IFIH1)

0.018

0.008

DDX58/IFIH1-mediated induction of interferonalpha/beta (IFIH1)

0.032

0.015

Inactivation, recovery and regulation of the
phototransduction cascade (GUCA1C)

0.012

0.005

The phototransduction cascade (GUCA1C)

0.012

0.005

Visual phototransduction (GUCA1C)

0.023

0.010
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Chapter 3 Figures

Figure 3.1. Flow diagram of the gVCF processing steps. These steps were taken prior to HA
and CH variant identification.
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Figure 3.2. The median number of variants per sample, across all disease types, after each
processing step where variants were excluded. The original gVCF files had a median of
5,509,545 unphased variants across all samples and diseases. Approximately 70.7% of the
variants were available for CH and HA identification after processing the original gVCF files. Of
the available variants, ~86.7% were phased on average.
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Figure 3.3. Percentage of 1000GP samples with a CH variant in a gene. Frequency represents
the number of genes that were observed at a specific percentage.
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Figure 3.4. Number of samples with potentially damaging CH or HA variants in genes
involved in developmental biology. No potentially damaging CH or HA variants were
identified in tumor suppressor genes.
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Figure 3.5. The landscape of potentially damaging CH variants. Each colored-box represents
a gene type (see legend). The values within each colored-box indicate how many samples for that
disease had a CH variant in that gene.
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trioPhaser: Using Mendelian Inheritance Logic to Improve Genomic Phasing of Trios
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Abstract
Background
When analyzing DNA sequence data of an individual, knowing which nucleotide was inherited
from each parent can be beneficial when trying to identify certain types of DNA variants.
Mendelian inheritance logic can be used to accurately phase (haplotype) the majority (67-83%)
of an individual's heterozygous nucleotide positions when genotypes are available for both
parents (trio). However, when all members of a trio are heterozygous at a position, Mendelian
inheritance logic cannot be used to phase. For such positions, a computer-based phasing
algorithm, such as SHAPEIT4, can be used. SHAPEIT4 can use pre-phased haplotypes to
increase phase accuracy but does not provide a way to produce this information. Therefore, we
created trioPhaser to combine the accuracy of Mendelian inheritance logic with SHAPEIT4 to
phase trios.

Results
trioPhaser uses gVCF files from an individual and his/her parents as initial input, and then
outputs a phased VCF file. Input trio data are first phased using Mendelian inheritance logic.
Then, the positions that cannot be phased using inheritance information alone are phased by
SHAPEIT4. Using whole-genome sequencing data of 50 trios, we show that trioPhaser, on
average, increases the total number of phased positions by 19.2% and 10.4% when compared to
the number of positions SHAPEIT4 or Mendelian inheritance logic can phase when either are
used alone, respectively. In addition, we show that the accuracy of the phased calls output by
trioPhaser are similar to linked-read and read-backed phasing.
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Conclusion
trioPhaser is a containerized software tool that uses both Mendelian inheritance logic and
SHAPEIT4 to phase trios when gVCF files are available. By implementing both phasing
methods, more variant positions are phased compared to what either method is able to phase
when used alone.
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Background
When analyzing whole-genome sequence (WGS) data of an individual, the parent of origin for
each nucleotide is often unknown [1, 2]. Investigators can identify homozygous-alternate and
simple-heterozygous variants, but more complex variants, such as compound-heterozygous
variants, are unidentifiable unless the genotype data are phased [3, 4]. Phasing (haplotyping) is a
process that helps differentiate between maternally and paternally derived nucleotides [1]. Phase
can be estimated with computer-based methods that rely on haplotype evidence from multiple
sources; different software programs may support one or more of the following sources:
haplotype reference panel, raw-sequence reads, and/or familial genotypes [1, 5, 6]. It has been
shown that using trio data (data from each parent and the child) as part of the phasing process
can improve the number of accurately phased genotypes [1]. In fact, approximately 67-83% of an
individuals’ heterozygous sites can be phased using Mendelian inheritance logic [1, 7].

Some computer-based phasing programs, such as SHAPEIT2 [8] and whatshap [6] can take
parental genotypes into consideration when making haplotype calls for the child. However, these
programs have limitations. For example, whatshap requires BAM and VCF files as input [6].
BAM files from WGS data can be over 100 gigabytes in size, thereby requiring extensive
computational storage when many samples are being analyzed [9]. SHAPEIT2 can use a single
input type or a combination of input types to estimate phase. Input types supported by
SHAPEIT2 include VCF files, BAM files, a haplotype reference panel, and parental genotypes
[8]. However, SHAPEIT2 only supports genome build GRCh37. Therefore, user VCF files that
were generated using GRCh38 or other genome builds require conversion to GRCh37 through a
process that inevitably causes many variants to be removed [10]. A newer phasing method,
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SHAPEIT4, does not take parental genotype data as direct input into the phasing program, but it
does allow pre-phased data to be used as input to increase the accuracy of haplotype calls, and it
does support data aligned with GRCh38 [5]. However, SHAPEIT4 does not provide a means to
pre-phase the data, nor does it retain all of the pre-phased data in the final output for variant
positions that are not listed in the haplotype reference panel file or that are multi-allelic. Thus,
we created trioPhaser, a single-step, containerized application that accepts gVCF files from a trio
as input, pre-phases the data using Mendelian inheritance logic, and then uses the pre-phased
data as input into SHAPEIT4, producing a phased VCF file (Fig. 4.1).

Our method overcomes some of the limitations that current phasing software presents, without
creating a completely new phasing algorithm. We are able to use the information that gVCF files
provide to pre-phase the data of the child using Mendelian inheritance as a guide. gVCF files are
different from VCF files in that both variant and invariant positions are included as part of the
file. This proves beneficial as parental genotype information can be compared to a child’s,
position for position, in an effort to determine which parent each nucleotide was inherited from.
This pre-phase step allows SHAPEIT4 to use a priori information as part of the phasing process
and outputs the data in a conventional format with the paternal allele first, followed by the
maternal allele. The phased output file generated by SHAPEIT4 excludes a priori positions that
are not contained in the haplotype reference panel or that are multi-allelic. Therefore, after
SHAPEIT4 phases the data, trioPhaser adds any Mendelian-phased positions to the final output
that were excluded.

Implementation
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Software
trioPhaser consists of a single Python (https://python.org) script (“trio_phaser.py”) that executes
within a Docker container [11]. This script provides logic for processing data files and invoking
third-party tools such as GATK [12] (version 4.0.5.1), bcftools [13] (version 1.9), and
SHAPEIT4 [5] (version 4.1.3). These tools are available within the container. Therefore, in order
to execute trioPhaser, the user needs only to install the Docker engine and download the Docker
image.

Inputs
trioPhaser has 5 required arguments: 1) gVCF file of the child, 2) gVCF file of the father, 3)
gVCF file of the mother, 4) name of the phased output file, and 5) path where haplotype
reference files will be saved. There are also 3 option arguments: 1) the number of CPU cores to
use for processing (default = 2), 2) which genome build the input files were created with (default
= GRCh38, GRCh37 is also supported), and 3) the minimum Phred-scaled quality score a variant
position is able to have (default = 30). When multiple cores are available, SHAPEIT4 will phase
multiple autosomal chromosomes simultaneously, thereby decreasing run-time.

Pipeline Design
Although trioPhaser executes with a single Python script, there are six steps performed by the
script in order to produce a phased VCF file. For step 1, the child’s gVCF file is used to produce
a temporary file that contains all variant positions. In addition, the gVCF files for each parent are
used to produce temporary VCF files that contain positions that are congruent with the child’s
retained variant positions. These positions may be variant or invariant as long as they are found
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within the newly created file. The purpose of this step is to retain pertinent information and
decrease the size of the files. Decreasing file sizes decreases runtime of subsequent steps.
Step 2 uses GATK’s “CombineGVCFs” tool to combine the temporary VCF files from Step 1
into a single file. Then, step 3 uses GATK’s “GenotypeGVCFs” tool to joint-genotype the calls.
Joint-genotyping can help determine if a poorly called variant is a “true” variant by comparing it
to the other samples.

Once genotyped, step 4 separates the file into 22 chromosome VCF files and creates a prephased file, or scaffold, for each chromosome. To create the scaffold files, Mendelian inheritance
logic is used. For positions of the child that can be determined which variant came from which
parent, the haplotypes of these positions are written to a temporary scaffold file. For example, if
the mother is homozygotic for the reference allele (A/A), the father is heterozygotic (A/G), and
the child is heterozygotic (A/G), then it can be determined that the reference allele (A) was
inherited from the mother and the variant allele (G) was inherited from the father. However,
when both parents and the child are heterozygotic (A/G), Mendelian inheritance alone cannot be
used to determine which nucleotide came from which parent. SHAPEIT4 uses surrounding prephased positions and information from the 1000 Genomes Project [14] haplotype reference panel
to phase such scenarios.

Step 5 uses the chromosome VCF files, the scaffold VCF files, and the haplotype reference
panel as input into SHAPEIT4 to phase each chromosome under default parameters. Only
positions that are in the haplotype reference panel and that are bi-allelic are included in the
phased VCF files output by SHAPEIT4. Therefore, step 6 uses the scaffold files and the
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SHAPEIT4-phased chromosome files to create a single VCF file that includes all Mendelianphased and SHAPEIT4-phased positions for each chromosome.

Results
trioPhaser Results on an Ashkenazim Trio
Whole-genome sequencing (WGS) data for an Ashkenazim trio were used to test trioPhaser.
Data for this trio were generated by the Genome in a Bottle (GIAB) Consortium [15]. We used
GRCh38-aligned BAM files (available through GIAB FTP server) as input into GATK’s
“HaplotypeCaller” tool to generate gVCF files for each member of the trio. The gVCF files were
then used as input into trioPhaser.

For the child of this trio, there were 5,477,879 genotyped variants. 4,640,241 (84.7%) of the
genotyped variants were phased by trioPhaser. 2,528,322 out of 3,700,540 (68.3%) heterozygous
variants were able to be phased using Mendelian inheritance logic. 867,181 (18.7%) of the
phased variants were phased exclusively with Mendelian inheritance logic and would not have
been included in the final output if using SHAPEIT4 alone. SHAPEIT4 phased 458,361 variants
that could not be phased using Mendelian inheritance logic. trioPhaser took 5.8 hours to execute
when using 22 CPU cores.

Comparison of trioPhaser to Linked-read Phasing Technology
In addition to BAM files, GIAB provides phased VCF files for each member of the Ashkenazim
trio. These data had been phased using linked-read technology [16] (10X Genomics) which is
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one of the most accurate phasing methods [1]. Therefore, we used this trio as our “gold standard”
to evaluate trioPhaser.

trioPhaser and 10X Genomics phased 4,640,241 and 4,442,906 variants, respectively. Of the
3,999,945 variants that were congruent (those that had the same position, reference allele, and
alternate allele) between the 10X-phased and trioPhaser-phased data, 3,952,525 (98.8%) of the
variants were phased the same. Of the congruent 10X-phased variants, 3,479,724 were able to be
validated using Mendelian inheritance and of these variants 3,455,831 (99.3%) were phased
correctly (assuming they were genotyped correctly).

Comparison of trioPhaser to whatshap
whatshap is a read-based phasing method that uses sequencing reads to reconstruct haplotypes
[6]. This phasing method requires BAM file(s) and a VCF file as input. Incorporating sequencing
reads as part of the phasing process can increase the overall accuracy of phase results [1].
Therefore, we phased the Ashkenazim trio using whatshap to compare the accuracy of readbacked phasing to trioPhaser. Before phasing with whatshap, we used GATK’s
“CombineGVCFs” tool to combine the gVCF files we previously created for the Ashkenazim
trio and then joint-genotyped the combined trio using GATK’s “GenotypeGVCFs” tool. This
joint-genotyped file and the GRCh38-aligned BAM files for each member of the trio were used
as input into whatshap. The phased VCF output by whatshap only includes heterozygous
positions. Therefore, we only compared heterozygous positions between trioPhaser and
whatshap.
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trioPhaser phased 2,986,350 heterozygous variants compared to 2,404,066 as phased by
whatshap. Of the 2,275,546 phased heterozygous variants that were congruent between
trioPhaser and whatshap, 2,204,240 (96.9%) were phased the same. 1,959,580 of the congruent
positions could be phased using Mendelian inheritance logic and 100% percent of these positions
were phased the same between trioPhaser and whatshap. whatshap took 26.6 hours to phase
compared to trioPhaser which took 5.8 hours.

trioPhaser Results Across 50 Trios
In addition to validating trioPhaser with GIAB data, we ran trioPhaser on 50 neuroblastoma trios
using gVCF files that were created using WGS data. These gVCF files are available through the
Gabriella Miller Kids First Data Resource Center [17]. On average, per proband, there were
4,469,479 of 5,976,380 (75%) variants phased by trioPhaser. Of the phased variants, 4,048,686
(90.6%) were able to be phased using Mendelian inheritance logic. ~76.7% of heterozygous
variant positions could be phased using Mendelian inheritance patterns alone. Of the Mendelian
phased variants, 721,415 would not have been phased if using SHAPEIT4 alone. There were
420,793 positions phased by SHAPEIT4 that could not be phased using Mendelian inheritance
logic. Execution time of trioPhaser was, on average, 4.4 hours per trio when using 22 CPU cores.
A detailed document explaining where data was downloaded from, how it was processed, and
how to run trioPhaser is available at
https://github.com/dmiller903/trioPhaser/blob/main/validate/validate.pdf

Conclusion
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trioPhaser is a containerized phasing tool that implements Mendelian inheritance logic and
SHAPEIT4 to phase trios. Using both phasing methods produces a greater overall number of
phased variants than would be output when using either method alone. In fact, on average,
trioPhaser increased the total number of phased variants by 19.2% and 10.4% when compared to
what SHAPEIT4 or Mendelian inheritance logic were able to phase when used alone,
respectively. We show that 98.8% of the congruent 10X-phased haplotype calls, and 96.9% of
the congruent whatshap haplotype calls are the same as trioPhaser. trioPhaser is a suitable
phasing alternative for trios when gVCF files are available or can be generated.
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Figures
Chapter 4 Figures

Figure 4.1. General overview of trioPhaser’s design. trioPhaser takes a gVCF from each
member of a trio as input, uses Mendelian inheritance logic and SHAPEIT4 to phase, and outputs
a phased VCF file for the child. trioPhaser is encompassed within a Docker container.
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Abstract
The genetic underpinnings of most pediatric-cancer cases are unknown. Population-based studies
use large sample sizes but have accounted for only a small proportion of the estimated
heritability of pediatric cancers. Pedigree-based studies are infeasible for most human
populations. One alternative is to collect genetic data from a nuclear family and use inheritance
patterns within the family to filter candidate variants. This approach can be applied to common
and rare variants, including those that are private to a given family or to an affected individual.
We evaluated this approach using genetic data from three nuclear families with 5, 4, or 7
children. Only one child in each nuclear family had been affected, and neither parent had been
diagnosed with cancer. Diagnoses for the affected children were benign low-grade astrocytoma,
Wilms tumor (stage 2), and Burkitt’s lymphoma, respectively. We used whole-genome
sequencing to profile normal cells from each family member and a linked-read technology for
genomic phasing, which enabled us to identify compound-heterozygous variants in addition to
simple-heterozygous, homozygous-alternate, and de novo variants. For initial filtering, we used
global minor allele frequencies, deleteriousness scores, and functional-impact annotations. Next,
we used genetic variation in the unaffected siblings as a guide to filter the remaining variants. As
a way to evaluate our ability to detect variant(s) that were relevant to disease status, the
corresponding author blinded the primary author to affected status; the primary author then
assigned a risk score to each child, guided by gene-disease associations and disease-likelihood
scores. Based on this evidence, the primary author predicted which child had been affected in
each family. The primary author's prediction was correct for the child who had been diagnosed
with a Wilms tumor. The predictions for the other two families were incorrect, although the child
with Burkitt’s lymphoma had the second highest risk score among the seven children in that
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family. This study demonstrates a methodology for filtering and evaluating candidate genomic
variants and genes within nuclear families that merits further exploration.
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Introduction
Genome-wide association studies (GWAS) have identified novel cancer susceptibility loci across
different pediatric cancer types1–4. However, in GWAS studies such as these, the research
participants are typically unrelated, and rare variants are not easily identified due to a lack of
statistical power5,6. Accordingly, these studies may fail to discover rare variants that are
responsible for some of the missing heritability of complex diseases 6. Family-based designs are
sometimes able to identify rare candidate variants when related, affected individuals have the
same variant in common7. For example, in co-segregation studies, researchers analyze related
individuals for variants that segregate with affected status. Perhaps the ideal co-segregation
design involves sequencing the DNA of individuals spanning many generations; however, these
samples are difficult to obtain for most human populations. A simpler, yet more feasible, familybased design involves sequencing trios (an affected child and both parents). This approach
enables investigators to identify the parent of origin for each variant under investigation, which
can help identify compound-heterozygous variants (when a proband inherits a variant from each
parent in the same gene) and de novo variants (when both parents lack a variant that is found in a
proband)8. Both of these variant types contribute to pediatric cancers and are relatively
understudied9,10.

An extension of the trio-based design is to study nuclear families in which DNA has been
collected from both parents and two or more children. In 2010, Roach et al., conducted the first
study showing the utility of using next-generation sequencing to profile a nuclear family (of
four)11,12. Both children had Miller syndrome and primary ciliary dyskinesia, which are
Mendelian disorders11. Analyzing whole genome sequencing (WGS) data across all members of
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the nuclear family, they narrowed the candidate genes for these diseases to four. More recently, a
2016 study by Stittrich et al. analyzed WGS data of five nuclear families, plus some extended
family members, to identify variants that conferred a risk for inflammatory bowel disease
(IBD)13. Nuclear family sizes (excluding extended family members) ranged from four to eight
individuals, with at least one child having been diagnosed with IBD. Extended family members
had been diagnosed with IBD or were suspected to have IBD. Using identity-by-descent of
affected and unaffected individuals from nuclear and extended family members in conjunction
with variant- and gene-level filters, they identified rare, novel variants that conferred a risk for
disease development. Protein modeling and a luciferase reporter assay were used to test potential
effects of the top candidate variant. These studies highlight that sequencing many members of a
nuclear family can provide insights that would not be provided through a trio-based approach. In
addition to identifying shared variants among siblings with the same disease, such designs can
provide a clearer understanding of the genetic underpinnings of a disease, even when only one
child has been diagnosed with the disease. For example, sequencing the DNA of all members of
a nuclear family may allow investigators to eliminate certain variants from being considered as
“disease-causing” when one or more healthy children have the same variant as the proband. On
the other hand, if a variant is considered disease-causing in the proband and this same variant is
found in a sibling, it may indicate that the non-proband child is susceptible to developing the
disease in the future; this methodology could be used for prenatal screening.

The state of Utah has the highest average birth rate (14.9 per 1,000 women) in the United States,
much higher than the national average (11.6)14. Accordingly, we saw this as an opportunity to
perform a pilot study to generate DNA sequence data of relatively large nuclear families for
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which a single child had been diagnosed with some form of pediatric cancer; this dataset would
allow us to further evaluate the potential to use DNA variants from unaffected children as a
guide when filtering candidate variants for the affected child. Via collaboration with a nonprofit
organization that supported families affected by pediatric cancer, we identified three Utah
families in which a single child had been diagnosed with some form of pediatric cancer and for
which at least four children had been born to the same parents. These families had 5, 4, or 7
children, for a total of 22 individuals (including parents) (Fig. 5.1). Diagnoses for the affected
children were benign low-grade astrocytoma, Wilms tumor, and Burkitt’s lymphoma,
respectively. Low-grade astrocytomas develop in the central nervous system and are the most
common brain tumor type in children15. Wilms tumor, one of the most common solid tumors
occurring in children, develops in the kidney16. Burkitt’s lymphoma is a type of non-Hodgkin
lymphoma that originates from B-cells17. For each nuclear family, we generated germline,
linked-read WGS data for each individual.

In sequencing all members of these nuclear families, we hoped to identify DNA variants that
were strong candidates as causal variants for each affected child. Two ways of validating such
candidates include observation in subsequent familial generations and lab-based functional
testing; however, waiting to observe subsequent generations is infeasible for families with young
children, and designing functional tests can be expensive and time consuming when evaluating
multiple variants of unknown clinical significance on an individual-sample basis18. As an
alternative form of validation, we evaluated whether we could use candidate DNA variants
within a nuclear family to make correct predictions in retrospect about which child had been
diagnosed with cancer. By random chance, it would be difficult to correctly predict the
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phenotypic status of all children in our study. The probability of predicting the correct affected
child by random chance for the individual families would be 1 in 5 (0.20), 1 in 4 (0.25), 1 in 7
(0.143), respectively. Using the general multiplication rule, the probability of making correct
predictions for all three families was 0.00715. Accordingly, if we were able to make such
predictions correctly, it would provide evidence that using DNA variation from unaffected
members of the same nuclear family merits further exploration as a guide for variant
interpretation. To test this idea, we used a blind-study format. The primary author (DBM)
analyzed the genomic data without any knowledge of which child in each nuclear family had
been diagnosed with pediatric cancer. Based on variant minor allele frequencies, deleteriousness
scores, functional-impact annotations, gene-disease association scores, and disease-likelihood
scores, DBM made predictions about which child had been diagnosed with cancer in each
family. He then deposited a summary of our research protocol and the individual-level
predictions in a preregistration repository on the Open Science Framework website19 (doi:
10.17605/OSF.IO/89Y67). After preregistration, SRP revealed the prior diagnosis status of each
child, and together they assessed the accuracy of the predictions.

Results
We generated germline, WGS data for three nuclear families (Fig. 5.1). Family 1 had 5 children,
whom we labeled with sample identifiers 25-29; one of these children had been diagnosed earlier
in life with a benign low-grade astrocytoma. Family 2 had 4 children, whom we labeled with
sample identifiers 32-35; one of these children had been diagnosed previously with a Wilms
tumor. Family 3 had 7 children, whom we labeled with sample identifiers 38-44; one of these
children had been diagnosed previously with Burkitt’s lymphoma. Author DBM used the genetic

118

data and associated annotations to make a prediction for each family about which child had been
diagnosed with cancer.

Summary of Identified Variants
Variant data included phased variants (SNPs), mid-scale deletions (indels), and large-scale
structural variants (SVs). The total number of passing variants (quality score >= 20 and filter
classification of “PASS”) was similar for most samples (Fig. 5.2). For each patient, we identified
simple-heterozygous, homozygous-alternate, and compound-heterozygous variants and filtered
the variants based on global minor allele frequencies (MAF), Combined Annotation Dependent
Depletion20 (CADD) scores, impact severity, and whether the variants were exonic (see
Methods; Fig. 5.3). For each of these variant types, we also examined whether the variants were
de novo (undetected in either parent) (Fig. 5.4). For Family 1, across all children, we identified
33 potentially damaging, simple-heterozygous variants and 1 potentially damaging homozygousalternate variant. Eight of the simple-heterozygous variants were de novo. Of the potentially
damaging variants identified in Family 2, 20 were simple heterozygous, 1 was compound
heterozygous, and 1 was de novo homozygous alternate. Of the simple-heterozygous variants, 6
were de novo. One of the heterozygous variants contributing to the compound-heterozygous
variant was de novo. Across all children in Family 3, we identified 30 potentially damaging,
simple-heterozygous variants and 7 potentially damaging, homozygous-alternate variants; 11 of
the simple-heterozygous variants and 3 of the homozygous-alternate variants were de novo. The
number of SNPs, indels, and SVs varied within families. For example, the number of SNPs per
child in Family 3 ranged from 5 to 9. Every child in Family 3 had at least one indel, but only 2 of
the 7 children had at least one SV. Similar trends are observed in Families 1 and 2.
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Variant and Gene Commonality Among Siblings
We assessed the potentially damaging variants and the gene(s) in which the variants were
identified for commonality among siblings (Table 5.1). We assumed that if multiple children
within a family had a potentially damaging variant in the same gene, then the gene was less
likely to influence disease development. However, we allowed for the possibility that two
children in a family might have a damaging variant. We supposed that if such a variant were
shared by the affected child and an unaffected sibling, the variant might influence tumorigenesis
later in life in the unaffected sibling. Another possibility is that epistasis may have occurred
between this damaging variant and another damaging variant in the affected child but the
interacting variant was not present in the unaffected sibling. This filtering step reduced the
number of candidate variants to 17, 17, and 23 in 15, 16, and 22 mutated genes for Family 1,
Family 2, and Family 3, respectively (Table 5.1 & Supplementary Table 5.1). Most of the
mutated genes were private within each family. For example, in Family 1, 10 mutated genes
were unique to any single child within the family, while the remaining 5 mutated genes were
shared by two children.

Gene Rankings and Pediatric Cancer Predictions
We evaluated each mutated gene using VarElect, which provides details from the literature about
gene-phenotype associations. We used this information to rank genes and score each patient (see
Methods). A complete list of genes with potentially damaging variants and the number of
samples with a potentially damaging variant in each gene is provided in Supplementary Table
5.1.
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The top-five ranked genes for Family 1 (benign low-grade astrocytoma) were FAM8A1, ACADS,
KRT76, HLA-DRB1, and TTBK2 (Supplementary Table 5.2). Based on our scoring methodology,
we predicted Sample 26 to have been the child diagnosed with cancer (Table 5.2). Sample 26 had
two simple-heterozygous SNPs in FAM8A1 (both on the same chromosome) and one simpleheterozygous SNP in ACADS. These SNPs resulted in early stop sequences in these genes. While
neither of the genes have directly been associated directly with low-grade astrocytomas, they are
involved in important cellular processes. FAM8A1 is a membrane protein that helps assemble
the HRD1 complex, which is part of the ubiquitin-proteasome-dependent process of
endoplasmic-reticulum-associated degradation (ERAD)21. This process targets misfolded
proteins, which are then degraded. The ACADS protein is a flavoenzyme that is involved in fatty
acid catabolism in the mitochondria22. A deficiency in ACADS production can inhibit some fats
from being converted to energy23.

For Family 2 (Wilms tumor), the top-five ranked genes were FAM8A1, TRPM3, PAH, PCK1,
and PCK2 (Supplementary Table 5.3). We predicted Sample 35 to have been the child diagnosed
with cancer (Table 5.3). This child had a de novo, simple-heterozygous deletion in FAM8A1,
leading to a frameshift; it also had simple-heterozygous SNPs in TRPM3 and PAH, leading to
early stop sequences in each gene. Interestingly, the top-ranked gene (FAM8A1) was identical to
the top-ranked gene for Family 1; however, as with low-grade astrocytomas, this gene has not
been associated directly with Wilms tumors. The TRPM3 protein functions as an ion channel to
allow calcium to pass through the surface of a cell24. Some mutations in this gene can create an
overactive ion channel. Altered expression of TRPM3 has been observed in glioblastoma25 but
not in Wilms tumors. PAH is an enzyme involved in phenylalanine catabolism26. Inherited,
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autosomal recessive defects in PAH can lead to phenylketonuria, a disease that causes physical
and mental abnormalities.

For Family 3 (Burkitt’s lymphoma), TNNT3, SIRPB1, TRMT1, ITGB4, and DCHS1 were the topfive ranked genes (Supplementary Table 5.4). Sample 43 had the highest score and was predicted
to be the child diagnosed with cancer (Table 5.4). This child had a de novo, simple-heterozygous
structural variant in TNNT3, leading to a transcript ablation, and a de novo, simple-heterozygous
SNP in ITGB4, creating an early stop sequence. Neither of these genes have been directly related
to Burkitt’s lymphoma. TNNT3 is a troponin T isoform that helps to control muscle contraction
through calcium regulation27. The ITGB4 gene codes for an integrin transmembrane receptor
involved in extracellular matrix interactions28. Altered expression of ITGB4 has been observed in
various cancers including lung and breast29,30.

Evaluation of Pediatric Cancer Predictions
After making our predictions for each family, author SRP revealed the cancer status of each
child. We found that one of the three predictions was correct—Sample 35 of Family 2 had been
diagnosed with a Wilms tumor. This sample had unique variants (not shared with other siblings)
in the top two ranked genes (FAM8A1, and TRPM3) and shared a simple-heterozygous SNP with
Sample 34 in the third ranked gene (PAH). Family 2 was the smallest of the three families; thus
the probability of making a correct prediction by random chance was highest for this family. In
Family 1, Sample 25 had been diagnosed with a benign low-grade astrocytoma but was ranked
fourth out of five children using our methodology. This individual had a simple-heterozygous
SNP in HLA-DRB1, the 3rd-ranked gene (tied with KRT76); no other child in the family shared
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this variant. The HLA-DRB1 protein plays a role in the immune system by presenting
extracellular antigens to helper T cells31. Variants in HLA-DRB1 have been associated with
multiple sclerosis31. In Family 3, Sample 41 was revealed to have had Burkitt’s lymphoma and
was ranked second out of seven children using our methodology. This individual had a de novo,
homozygous structural variant in SIRPB1, the 2nd overall ranked gene for Burkitt’s lymphoma;
no other child in the family shared this variant. SIRPB1 is involved in cell signaling as a
transmembrane glycoprotein receptor and may be associated with immunodeficiencies 32,33.

Discussion
Our methodology is unconventional relative to prior studies. Different from population-based,
genetic studies that seek to identify variants or genes of interest, we attempted to predict proband
status for an individual child in a given nuclear family. Our approach may provide insight into
variants and genes that have influenced disease development within a given family but not
necessarily for the broader population. Different from studies that use genotypic markers to
derive risk scores based on population-based frequencies34, we used inheritance patterns within
nuclear families, supplemented by variant annotations and literature-based evidence.

Accordingly, our approach is a mixture of quantitative and qualitative methods. Quantitatively,
we used global minor allele frequencies, deleteriousness scores, functional-impact annotations,
prior disease associations, and co-occurrence among siblings to inform variant- and gene-level
filtering. However, to derive a single prediction per family, qualitative judgment was necessary
to define filtering thresholds and to combine the multiple lines of evidence. Some combinations
of thresholds and evidence aggregation may have resulted in accurate predictions for all three
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families, while many other combinations would not. Therefore, our question was not whether it
would be possible to identify such patterns but whether we could make accurate predictions
without knowing proband status a priori. Accordingly, we blinded the primary author and made
our predictions publicly available before proband stata were revealed to the primary author.
Only one of the three predictions that we made was correct, suggesting that germline variation
and currently available ancillary information provide insufficient information to make accurate
predictions and/or that our prediction methodology requires further refinement. Furthermore,
tumorigenesis often results from at least one mutation inherited in germline cells and at least one
mutation that has occurred sporadically in somatic tissue35. Our methodology does not account
for somatic mutations nor epigenetic factors, such as aberrant DNA methylation, that may play a
role in tumor development36.

Relative to prior research, our study is unique in that the family sizes were large (four to seven
children), and only one child in each family had been diagnosed with a pediatric tumor. In
addition, our use of linked-read WGS enabled us to estimate phase reliably and thus identify de
novo and compound-heterozygous variants. Sequencing a large number of children in each
family allowed us to filter out variants that were common among multiple siblings, potentially
excluding genes that are less likely to contribute to pediatric cancer development. By using
VarElect to evaluate known gene-disease connections and disease likelihood, we were able to
consider complementary types of literature-based evidence. Averaging these ranks helped make
our prediction process more objective and prevented us from being influenced unduly by either
type of evidence.
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After the proband status was revealed for each family, we considered whether differences in
sequencing coverage may have biased our analysis. Even though the average sequencing
coverage per base varied somewhat across samples, on average, 72.6% of sequenced variants
passed our quality filters. The probands were among the samples with the highest number of
passing variants and the highest percentage of phased variants. Therefore, if any samples were
favored by such a bias, the probands would have been.

We considered alternative strategies that we could have used to make predictions. One approach
would have been to assume that a relatively large number of potentially damaging variants
spanning diverse variant classes (SNPs, indels, and SVs) would result in a higher likelihood that
a given child would harbor a truly damaging variant. A chi-squared goodness-of-fit test revealed
that the total number of potentially damaging variants did not differ significantly among the
children in any of the families (p = 0.80, 0.37, 0.87). Anecdotally, in Family 1, the proband had
the smallest number of variants (SNPs only); in Family 2, the proband had the largest number of
variants (SNPs and indels, including one compound-heterozygous SNP); in Family 3, the
proband had the median number of variants (SNPs, indels, SVs). Therefore, basing our
predictions on the number and/or diversity of potentially damaging variants would not have led
to higher accuracy. Another alternative approach would be to focus on cancer-associated genes.
Hundreds of genes have been associated with cancer, mostly in adults 37. Across all samples, we
identified potentially pathogenic variants RGPD3 and CRNKL1. However, for both cancerassociated genes, mutations were not exclusive to the proband in which they occurred.
Having sequencing data from parents enabled us to identify de novo variants, which may have
been overlooked otherwise. We identified at least one potentially damaging, de novo variant in
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every child, across all families (Fig. 5.4). De novo variants develop during gametogenesis and
then are transmitted from parent to child; alternatively they can occur during early
embryogenesis8,38. Therefore, by definition, most de novo variants are rare and should rarely cooccur among siblings within a particular family. Across all families, 23 of the 28 de novo
variants that we observed were unique to a single child. It is possible that the remaining, shared
variants were a result of sequencing errors, and filtering by co-occurrence among siblings helped
mitigate this potential issue, as 4 of the 5 shared variants were excluded after this filtering step.
Overall, genes with de novo variants contributed heavily to our predictions. In particular, for
Family 3, all top-ranked genes had a de novo variant that was unique to a single child. For
Family 2, three of the five top-ranked genes had a de novo variant.

A key assumption behind our methodology is that if accurate predictions of proband status can
consistently be made for nuclear families, the germline variants used to make those predictions
may have translational relevance for those families. For example, any such variants that overlap
between the affected child and a sibling could be used to indicate cancer risk for the unaffected
sibling; having this knowledge could allow parents and clinicians to be more informed and more
effectively monitor disease risk. This approach could also be useful for prenatal screening. These
potential benefits warrant additional research and further refinement of our methodology.

Methods
Data Collection
We obtained approval for this study from Brigham Young University's Institutional Review
Board (study identifier: X15248). Each nuclear family consisted of a child who had previously
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been diagnosed with a pediatric tumor, siblings who had not been diagnosed with a pediatric
tumor, and both of the affected child's parents. Each affected child was in remission at the time
of data collection. Pediatric cancer types included benign low-grade astrocytoma, Wilms tumor
(stage 2), and Burkitt’s lymphoma. The families had five, four, and seven children, respectively.
All family members participated. We obtained signed consent forms from parents and children
using age-appropriate consent forms that parents also signed. The consent documents informed
participants that de-identified data would be uploaded to a public genomic repository.

We collected a saliva sample from each participant using Oragene 500 collection tubes. After
collecting these samples, SRP assigned a random, unique identifier to each participant and
labeled the saliva sample with this identifier. A random family identifier was also assigned to the
individuals so that family relationships could be determined in a de-identified manner.
Personally identifiable information was stored separately from the sequencing data so that these
types of data could not be directly linked without having access to both sources. DBM undertook
the task of making predictions about which child had been diagnosed with a tumor in each
family; he was not involved in recruiting participants, collecting information from the
participants, or generating the unique identifiers. At the time when he made the predictions, he
was unaware of which child had been diagnosed with a tumor. SRP played no role in making the
predictions but was aware of the methods DBM used to make the predictions.

DNA Sequencing and VCF Generation
The Genomic Services Lab at the HudsonAlpha Institute for Biotechnology extracted DNA from
the saliva samples and performed quality checks based on DNA concentrations and bacterial
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contamination. They performed DNA library preparation using the 10X Genomics Chromium
platform. Next, they performed paired-end, whole-genome sequencing using an Illumina HiSeq
X system. The reads were 150 bp in length.

Raw, linked-read39 sequences were assessed for quality, trimmed, and aligned to human
reference genome GRCh38 (sub-version 2.1.0) using version 2.1.3 of the Long Ranger40
software. The average coverage per base across the genome for all samples was 35.13. The
highest average coverage per base was 43.14, and the lowest average coverage per base was
19.92. These differences among the samples may be due to bacterial contamination or other
factors. Long Ranger was used to call variants (SNPs, indels, and structural variants). In addition
to its own logic, Long Ranger uses algorithms from BWA (alignment)41, Freebayes (variant
calling)42, and Genome Analysis Toolkit (variant calling)43. The results of this process were VCF
(Variant Call Format)44 files.

VCF Processing
For each step of VCF filtering, we used a Docker image (available at
https://hub.docker.com/r/dmill903/compound-het-vip) that encapsulated the software tools as
well as Python (https://python.org) scripts. The source code is available at
https://github.com/dmiller903/PedFam. Some of the scripts used during the variant-filtering
process were adapted from CompoundHetVIP45. A detailed document showing how the VCF
files were processed is available at
https://github.com/dmiller903/PedFam/blob/master/code_used_to_analyze_data.pdf
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Long Ranger produced 3 VCF files for each sample: 1) phased SNPs, 2) phased mid-scale indels,
and 3) phased large-scale SVs. The variants in each of these files were filtered based on quality
scores (>= 20) and a filter classification of “PASS”. bcftools46 (version 1.9) was used to combine
the SNPs from each sample into a single file, to combine the indels from each sample into a
single file, and to combine the SVs from each sample into a single file. This resulted in three
different files, each containing data for all 22 samples; these three files were processed
separately in all remaining steps.

The SNP file was normalized and left aligned using vt tools47 (version 2015.11.10). vt tools only
supports VCF files containing single-nucleotide variants; therefore the indel and SV files were
not able to be normalized and left aligned. Next, the SNP, indel, and SV files were annotated
using snpEff48 (version 4.3t). After annotation, vcf2db (https://github.com/quinlan-lab/vcf2db)
was used to create databases compatible with GEMINI49 (version 0.30.2). vcf2db separated the
annotations at each variant position into fields that could be queried; these fields included the
impact severity, whether the variant was exonic, etc. This final step of VCF processing produced
separate GEMINI databases for SNPs, indels, and SVs.

Variant Filtering
The SNP GEMINI database was queried for simple-heterozygous, homozygous-alternate,
compound-heterozygous, and de novo variants. When identifying simple-heterozygous and de
novo variants, we retained variants that had a scaled CADD score greater than 20, a MAF less
than 0.01 based on gnomAD50, an impact severity of “HIGH”, and that had been classified as
“exonic”. We classified these variants as "potentially damaging."

129

For compound-heterozygous variant identification, we retained variants that had a scaled CADD
score greater than 20, an impact severity of “HIGH”, and that had been classified as “exonic”.
We considered these variants to be potentially damaging. For MAF filtering, we required one
variant in a given gene to have a MAF smaller than 0.01 but allowed the second variant in the
same gene to have a MAF of any value. This allowed for scenarios where a rare allele was paired
with a relatively common allele, yet the combined population frequency of the two variants was
estimated to be low and thus may be more likely to be disease associated. If a child and either
healthy parent had the same compound-heterozygous variant, or if one of the alleles that was part
of the compound-heterozygous variant was a homozygous alternate in the parent of origin, it
would not likely be disease causing51. Thus of the identified compound-heterozygous variants,
we retained those that were unique to the child (i.e. not present in either parent). In addition,
when identifying compound-heterozygous variants, we excluded from consideration any variants
that were homozygous alternate in either parent.

When identifying homozygous-alternate variants, we retained variants that had a scaled CADD
score greater than 20, a global MAF less than 0.01 based on gnomAD, an impact severity of
“HIGH”, and had been classified as “exonic”. We considered these variants to be potentially
damaging. In addition, we excluded from consideration any homozygous-alternate variant that
was shared between parent and child as it is unlikely that these variants would be disease causing
if observed in a healthy parent51.
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When we queried the indel and SV GEMINI databases for simple-heterozygous, homozygousalternate, compound-heterozygous, and de novo variants, we used all of the above criteria except
for MAF and CADD thresholds. Many of the variants identified as indels or SVs did not have
CADD scores or MAF values, most likely due to their rarity in the general population.
Finally, we combined all identified potentially damaging variants into a single dataset using R52
(version 4.0.3) and the tidyverse packages53 (version 1.3.0). We identified genes that had at least
one child but no more than two children per family with any type of variant (homozygous
alternate, simple heterozygous, compound heterozygous, or de novo) identified as part of any
type of alteration (SNP, indel, SV).

Pediatric Cancer Predictions
One goal of this study was to evaluate whether we could predict which child in each family had
been diagnosed with cancer based solely on DNA variation and the genes in which those variants
were identified. As a first step, for each disease, we specified the genes associated with each
filtered variant as input to VarElect54. VarElect makes predictions about which gene or genes are
likely to affect phenotypes, either directly or indirectly through gene-gene interactions. VarElect
provides a score for each gene indicating the strength of connection between the gene and
phenotypes. In addition, a disease likelihood score is provided for each gene that is based on
Gene Damage Index55 and residual variation intolerance56 scores. We ranked each gene
separately based on these scores. For example, the highest connection score received a rank of
one, the second-highest connection score received a rank of two, etc. We ranked the disease
likelihood scores using the same logic. We then averaged these two ranked scores for each gene.
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To make a prediction about which child had been diagnosed with cancer in each family, we
focused on the five genes with the lowest average rank per family. We generated an aggregate
score for each child who had at least one variant in the five genes, based on the gene ranks. If a
given child had a variant in the top-ranked gene, we increased that child's score by 5; if a child
had a variant in the second-ranked gene, we increased that child's score by 4; and so on. If more
than one child had a variant in one of the ranked genes, the value for that ranked gene was evenly
divided among the samples with a variant in that gene. For example, if two children had a variant
in the first ranked gene, each child was given a score of 2.5 for that gene; this logic gave a lower
priority to variants that were shared among siblings. We then summed these scores for each
child. For example, if a child had a unique variant (not present in any other siblings) in the 1st
and 4th-ranked genes, we assigned an aggregate score of 7 to that child. The child with the
highest total score in each family was predicted to have been diagnosed with a pediatric tumor.

Data Availability
Aligned BAM files from this study are available from the European Genome-Phenome Archive
(accession: EGAS00001005321). The BAM files can be used to identify phased SNPs, indels,
and structural variants.
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Tables and Figures
Chapter 5 Tables
Table 5.1. An overview of variant and gene commonality for each nuclear family. One child
in Family 1 was diagnosed with a benign low-grade astrocytoma, one child in Family 2 was
diagnosed with Wilms tumor, and one child in Family 3 was diagnosed with Burkitt’s
lymphoma. Potentially damaging variants are those that met specific MAF, CADD and impact
severity thresholds (see Methods). Potentially damaging genes contained a potentially damaging
variant.

Family 1

Family 2

Family 3

Number of
Children with a
Potentially
Damaging Variant
1
2
3
4
5
1
2
3
4
1
2
3
4
5

Number of
Potentially
Damaging
Variants
12
5
7
6
3
12
5
4
2
15
8
5
5
1
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Number of
Children with a
Potentially
Damaging Gene
1
2
3
4
5
1
2
3
4
1
2
3
4
5

Number of
Potentially
Damaging Genes
10
5
6
6
3
11
5
4
2
14
8
4
4
2

Table 5.2. Top five candidate genes for Family 1 (benign low-grade astrocytoma). We
ranked genes based on the average gene-disease connection and disease likelihood scores
(Supplementary Table 5.2). The gene scores were equally divided among the samples when more
than one sample shared a variant in that gene. Red indicates which child was predicted to have
had cancer; blue indicates the child who had cancer. Sample 26 had simple-heterozygous, SNP
variants in the top 2 genes and was predicted to have had benign low-grade astrocytoma based on
having the highest aggregate gene score of 6.5. Abbreviations: het = simple heterozygous. del =
deletion.

Gene

Gene
Rank

FAM8A1
1st
ACADS
2nd
KRT76
3rd (tie)
HLA-DRB1 3rd (tie)
TTBK2
5th

Gene
Score
5
4
3
3
1

Sample (type of variant(s);
Sample (gene score
number of potentially
points awarded)
damaging variants)
26 (het SNP; n=2), 28 (het
26 (2.5), 28 (2.5)
SNP)
26 (het SNP)
26 (4)
29 (het SNP)
29 (3)
25 (het SNP)
25 (3)
27 (het del), 29 (het del)
27 (0.5), 29 (0.5)
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Table 5.3. Top five candidate genes for Family 2 (Wilms tumor). We ranked genes based on
the average gene-disease connection and disease likelihood scores (Supplementary Table 5.3).
The gene scores were equally divided among the samples when more than one sample shared a
variant in that gene. Green indicates a correct cancer prediction (cancer status revealed after
predictions were made). Sample 35 had simple-heterozygous variants (either SNP or deletion) in
the top 3 genes and was predicted to have had Wilms tumor based on having the highest
individual score of 10.5. Abbreviations: het = simple heterozygous. del = deletion.

Gene

Gene
Rank

FAM8A1
1st
TRPM3
2nd
PAH
3rd (tie)
PCK1 3rd (tie)
PCK2
5th

Gene
Score
5
4
3
3
1

Sample (type of variant(s);
Sample (gene score
number of potentially
points awarded)
damaging variants)
35 (de novo het del)
35 (5)
35 (het SNP)
35 (4)
34 (het SNP), 35 (het SNP)
34 (1.5), 35 (1.5)
33 (de novo het del)
33 (3)
33 (de novo het del)
33 (1)
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Table 5.4. Top five candidate genes for Family 3 (Burkitt's lymphoma). We ranked genes
based on the average gene-disease connection and disease likelihood scores (Supplementary
Table 5.4). The gene scores were equally divided among the samples when more than one
sample shared a variant in that gene. Red indicates the child predicted to have cancer and blue
indicates the actual child with cancer (cancer status revealed after predictions were made).
Sample 43 had simple-heterozygous variants (either SNP or structural variant) in 2 of 5 genes
and was predicted to have had Burkitt's lymphoma based on having the highest individual score
of 7. Abbreviations: het = simple heterozygous. hom = homozygous. del = deletion. SV =
structural variant.

Gene

Gene
Rank

Gene
Score

TNNT3
SIRPB1
TRMT1
ITGB4
DCHS1

1st
2nd
3rd
4th
5th

5
4
3
2
1

Sample (type of variant(s);
Sample (gene score
number of potentially
points awarded)
damaging variants)
43 (de novo het SV)
43 (5)
41 (de novo hom SV)
41 (4)
44 (de novo het SNP)
44 (3)
43 (de novo het SNP)
43 (2)
42 (de novo het del)
42 (1)
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Chapter 5 Figures

Figure 5.1. Structure of each nuclear family. Values underneath each child are sample
identifiers. These identifiers do not necessarily correspond to birth order or any other factor.
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Figure 5.2. The number of passing variants output from Long Ranger, and the percentage
of those passed variants that were phased. Passing variants were those that had a “PASS” in
the filter column of the VCF and a quality score >= 20. These numbers are summarized over all
variant categories. In order of the samples listed in the figure, the number of total variants output
from Long Ranger per sample were 5.89 x 106, 5.95 x 106, 6.11 x 106, 6.00 x 106, 6.22 x 106,
5.79 x 106, 5.80 x 106, 6.12 x 106, 6.02 x 106, 6.07 x 106, 5.72 x 106, 5.83 x 106, 6.58 x 106, 6.25
x 106, 6.19 x 106, 6.40 x 106.
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Figure 5.3. Summary of potentially damaging variant types. We show the number of
potentially damaging variants for each variant type and category for each sample.
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Figure 5.4. Summary of de novo variants. We show the number of variants that were de novo
for each variant category for each sample.
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Appendix 1: Supplementary Tables for Chapter 1
Supplementary Tables can be viewed and downloaded at
https://www.frontiersin.org/articles/10.3389/fgene.2020.00493/full#supplementary-material
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Appendix 2: Supplementary Tables for Chapter 3
Supplementary Tables can be viewed and downloaded at
https://www.frontiersin.org/articles/10.3389/fgene.2021.640242/full#supplementary-material
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Appendix 3: Supplementary Tables for Chapter 5
Supplementary Table 1, Chapter 5. The number of children with a potentially damaging
variant per gene per family. Bolded genes (genes with 2 or less children harboring a potentially
damaging variant) were used as part of VarElect analysis.
Family
Family 1
Family 1
Family 1
Family 1
Family 1
Family 1
Family 1
Family 1
Family 1
Family 1
Family 2
Family 2
Family 2
Family 2
Family 2
Family 2
Family 2
Family 2
Family 2
Family 2
Family 2
Family 3
Family 3
Family 3
Family 3
Family 3
Family 3
Family 3
Family 3
Family 3
Family 3
Family 3
Family 3
Family 3
Family 3
Family 1
Family 1
Family 1

Gene
ACADS
ALG1L2
GOLGA6L1
GOLGA6L2
HLA-DRB1
KRT76
RP11-294C11.1
SIRPB1
SPAG11B
Y_RNA
ANKRD36C
DPY19L3
FAM8A1
HLA-DRB1
HLA-DRB5
PCK1
PCK2
SIPA1L3
TRPM3
Y_RNA
ZAN
C1orf50
C2orf16
CCDC179
DCHS1
GLYATL1
ITGB4
KRTAP10-12
LILRA2
SIRPB1
SPAG11B
TNNT3
TRMT1
USP17L15
ZNF826P
FAM8A1
GUCA1C
SPATA31A6

Number of Children with Potentially Damaging Variant
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
2
2
2

149

Family 1
Family 1
Family 2
Family 2
Family 2
Family 2
Family 2
Family 3
Family 3
Family 3
Family 3
Family 3
Family 3
Family 3
Family 3
Family 1
Family 1
Family 1
Family 1
Family 1
Family 1
Family 2
Family 2
Family 2
Family 2
Family 3
Family 3
Family 3
Family 3
Family 1
Family 1
Family 1
Family 1
Family 1
Family 1
Family 2
Family 2
Family 3
Family 3
Family 3
Family 3
Family 1
Family 1
Family 1
Family 3
Family 3

TTBK2
XIRP2
CYP2A13
GOSR2
PAH
PNPLA7
RP1L1
ADGRA2
CSNK1A1
DNTTIP2
ENPEP
RGPD3
RNU7-167P
Y_RNA
ZNF99
CBWD5
CRNKL1
DAPL1
DUOXA1
RNU7-167P
ZNF486
ARHGEF38
LIN37
PCDHB7
WDR89
NDUFA5
SLC26A8
TTBK2
WDR89
ACOXL
IL1A
PSG9
QPCT
SECTM1
WDR89
SEMG2
ZYG11A
C1orf185
DUS4L
OR8G1
VIT
BST1
RGPD3
RNF6
CBWD5
PRSS57

2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
3
3
3
3
3
3
3
3
3
3
3
3
3
3
4
4
4
4
4
4
4
4
4
4
4
4
5
5
5
5
5
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Supplementary Table 2, Chapter 5. Genes with potentially damaging variants for lowgrade astrocytoma. We included genes that had at least one child but no more than two with a
potentially damaging variant. Scores provided by VarElect, our ranked version of the VarElect
scores, and our overall ranking are shown for each gene. RP11-294C11.1, SPATA31A6, XIRP2,
and Y_RNA were also identified in 2 or less children with potentially damaging variants, but
were not able to be ranked by VarElect. The number of potentially damaging variants in each
gene is one unless specified with n. Abbreviations: het = simple heterozygous. SNP = single
nucleotide polymorphism. del = deletion. SV = structural variant.
Gene
Symbol

VarElect:
GeneDisease
Connection
Score

GeneDisease
Connection
Rank

VarElect:
Average
Disease
Causing
Likelihood

FAM8A1

0.64

4

84.12%

ACADS

0.68

3

38.80%

KRT76

0.80

2

2.48%

HLA-DRB1

1.22

1

0.99%

TTBK2

0.31

7

47.03%

SIRPB1

0.41

5

36.52%

GUCA1C

0.33

6

17.59%

SPAG11B

0.01

10

50.45%

GOLGA6L2 0.24

8

0.00%

ALG1L2

9

0.00%

10

0.00%

0.07

GOLGA6L1 0.01
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Disease
Average Gene Sample
Causing
Rank
Rank (type of
Likelihood
variant(s);
Rank
number
of
potentially
damaging
variants)
26 (het
SNP; n=2),
28 (het
1
2.5
1st
SNP)
26 (het
4
3.5
2nd
SNP)
29 (het
7
4.5
3rd
SNP)
25 (het
8
4.5
3rd
SNP)
27 (het
del), 29
3
5
5th
(het del)
28 (de
novo het
5
5
5th
SV)
28 (het
SNP), 29
6
6
7th
(het SNP)
27 (de
novo het
2
6
7th
SNP)
28 (de
novo het
9
8.5
9th
del)
29 (de
novo het
9
9
10th
SV)
26 (het
9
9.5
11th
SNP)

Supplementary Table 3, Chapter 5. Genes with potentially damaging variants for Wilms
tumor. We included genes that had at least one child but no more than two with a potentially
damaging variant. Scores provided by VarElect, our ranked version of the VarElect scores, and
our overall ranking are shown for each gene. Y_RNA was also identified in 2 or less children
with potentially damaging variants, but were not able to be ranked by VarElect. Abbreviations:
het = simple heterozygous. hom = homozygous. SNP = single nucleotide polymorphism. del =
deletion. SV = structural variant. CH = compound heterozygous.
Gene
Symbol

VarElect:
GeneDisease
Connection
Score

GeneDisease
Connection
Rank

VarElect:
Average
Disease
Causing
Likelihood

Disease
Causing
Likelihood
Rank

FAM8A1

10.18

2

84.12%

1

TRPM3

10.89

1

51.71%

3

PAH

7.41

5

48.92%

4

PCK1

7.71

4

36.93%

5

PCK2

7.73

3

16.34%

8

DPY19L3

1.01

14

77.39%

2

SIPA1L3

5.46

9

18.80%

7

GOSR2

5.12

11

27.02%

6

CYP2A13

5.85

8

11.90%

9
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Average Gene Sample
Rank
Rank (type of
variant(s);
number
of
potentially
damaging
variants)
1.5
1st
35 (de
novo het
del)
2
2nd
35 (het
SNP)
4.5
3rd
34 (het
SNP), 35
(het SNP)
4.5
3rd
33 (de
novo het
del)
5.5
5th
33 (de
novo het
del)
8
6th
33 (het
SNP)
8
6th
32 (de
novo hom
del)
8.5
8th
33 (het
SNP), 34
(het SNP)
8.5
8th
32 (het
SNP), 33
(het SNP)

PNPLA7

5.94

7

5.70%

10

8.5

8th

HLA-DRB5

6.83

6

0.00%

13

9.5

11th

ANKRD36C 5.27

10

0.00%

13

11.5

12th

RP1L1

1.28

13

0.09%

12

12.5

13th

ZAN

4.51

12

0.00%

13

12.5

13th

HLA-DRB1

0.32

15

0.99%

11

13

15th
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32 (het
SNP), 33
(het SNP)
35 (de
novo het
SNP)
35 (de
novo het
SNP)
34 (het
SNP), 35
(het SNP)
32 (het
SNP)
35 (CH
SNP with
one variant
being de
novo)

Supplementary Table 4, Chapter 5. Genes with potentially damaging variants for Burkitt's
lymphoma. We included genes that had at least one child but nor more than two with a
potentially damaging variant. Scores provided by VarElect, our ranked version of the VarElect
scores, and our overall ranking are shown for each gene. CCDC179, RNU7-167P, and Y_RNA
were also identified in 2 or less children with potentially damaging variants, but were not able to
be ranked by VarElect. Abbreviations: het = simple heterozygous. hom = homozygous. SNP =
single nucleotide polymorphism. del = deletion. SV = structural variant.
Gene
Symbol

VarElect:
GeneDisease
Connection
Score

GeneDisease
Connection
Rank

VarElect:
Average
Disease
Causing
Likelihood

Disease
Causing
Likelihood
Rank

Average Gene
Rank
Rank

TNNT3

17.09

4

73.86%

2

3

1st

SIRPB1

22.43

2

36.52%

8

5

2nd

TRMT1

6.24

10

74.68%

1

5.5

3rd

ITGB4

15.55

6

49.08%

6

6

4th

DCHS1

22.99

1

12.37%

12

6.5

5th

ENPEP

6.53

9

40.03%

7

8

6th

C2orf16

10.82

7

14.20%

11

9

7th

LILRA2

7.00

8

14.24%

10

9

7th

ADGRA2

3.72

14

53.09%

4

9

7th

CSNK1A1

21.26

3

0.00%

16

9.5

10th

GLYATL1

1.34

17

65.38%

3

10

11th
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Sample
(type of
variant(s);
number
of
potentially
damaging
variants)
43 (de novo
het SV)
41 (de novo
hom SV)
44 (de novo
het SNP)
43 (de novo
het SNP)
42 (de novo
het del)
42 (het
SNP), 43
(het SNP)
44 (de novo
het SNP)
38 (de novo
het SNP)
40 (het
SNP), 43
(het SNP)
40 (het
SNP), 42
(het SNP)
41 (de novo
het SNP)

C1orf50

16.09

5

0.00%

16

10.5

12th

DNTTIP2

5.68

12

29.25%

9

10.5

12th

SPAG11B

1.33

18

50.45%

5

11.5

14th

KRTAP10- 5.76
12
ZNF99
5.28

11

11.09%

13

12

15th

13

9.06%

14

13.5

16th

RGPD3

1.86

15

4.61%

15

15

17th

ZNF826P

1.52

16

0.00%

16

16

18th

USP17L15

0.72

19

0.00%

16

17.5

19th

155

43 (het
SNP)
38 (het
SNP), 44
(het SNP)
39 (de novo
hom SNP)
39 (de novo
het del)
40 (het
del), 44
(het del)
38 (het
SNP), 42
(het SNP)
41 (de novo
het SV)
42 (de novo
hom SNP)

